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  i 
Abstract 
Pathogenic streptococci have evolved specific systems to eliminate bacterial competitors 
within their biological niche. In microbial environments, niche competition is often driven 
by the production of short antimicrobial peptides called bacteriocins; this provides a 
mechanism by which Streptococcus pyogenes may compete for ecological stability and 
establish infection. Recent findings from our laboratory have identified two novel Class IIb 
bacteriocin systems – Streptococcus pyogenes bacteriocin (Spb) JK and MN in the M18 
serotype S. pyogenes strain MGAS8232 – that may contribute to nasopharyngeal infection. 
Here, we show that galactose and CO2 are distinct regulatory cues which induce 
antimicrobial activity. Under these conditions, bacteriocin-producing strains inhibit the 
growth of other Gram-positive bacteria in vitro. We also demonstrate that acute infection 
in the nasopharynx of mice is dependent on the expression of at least one functional 
bacteriocin system. When mice are challenged intranasally with a double-bacteriocin 
knockout, the bacterial burden is dramatically reduced compared to the wild-type and single 
bacteriocin mutant controls. Furthermore, we show that nasal coinfection with S. pyogenes 
wild-type and DspbJKMN results in a wild-type dominant population, suggesting that 
bacteriocins enhance bacterial fitness in a polymicrobial environment. Taken together, 
these observations demonstrate that S. pyogenes secretes bacteriocins which contribute to 
the establishment of nasopharyngeal infection.  
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1.1 Streptococcus pyogenes 
Streptococcus pyogenes, also known as group A Streptococcus (GAS), is a Gram-positive 
extracellular bacterial pathogen with strict human tropism. This aerotolerant anaerobe 
grows in chains of varying lengths and is often identified by the unique b-hemolytic 
morphology it exhibits when grown on blood agar (1). The core-genome of S. pyogenes is 
composed of a single circular chromosome that is ~1.8 Mbp with a low G+C content of 
~39%, and encodes genes mainly involved in pathogenicity and virulence (2). Inside the 
pan-genome, there is repertoire of virulence genes that are highly variable among bacterial 
strains. These differences in non-essential genes are acquired via horizontal transfer of 
exogenous genetic elements; a process fundamental to streptococcal evolution (3–5). With 
a highly diverse genome, S. pyogenes is able to colonize human skin and mucosal surfaces, 
including the throat, vagina and rectum, but is also able to cause a wide range of diseases. 
These illnesses often manifest into mild cases of pharyngitis and impetigo but may also 
lead to invasive diseases such as necrotizing fasciitis and streptococcal toxic shock 
syndrome during severe infection. S. pyogenes has also been implicated in the development 
of post-infection sequelae, including acute rheumatic fever, rheumatic heart disease and 
glomerulonephritis. The Lancefield serological classification system based on surface 
carbohydrate expression has identified S. pyogenes as the only member of the group A 
streptococci. However, emm typing, which involves sequencing of the hypervariable region 
of the M protein gene, has emerged as the dominant method of classification, identifying 
over 200 GAS serotypes to date (1, 6, 7).  
 
1.2 Global disease burden of group A Streptococcus 
S. pyogenes is the etiological agent of a broad spectrum of disease. Despite its major 
contributions to human morbidity and mortality, the global importance of GAS remains 
largely under-recognized. Systematic reviews over the last decade have estimated the 
global burden of GAS disease using population-based analyses where possible. However, 
due to unreliable disease surveillance – particularly in regions where S. pyogenes has the 
greatest impact (i.e., developing countries) – the absolute burden of streptococcal diseases 




Superficial S. pyogenes skin (impetigo and pyoderma) infections and acute pharyngitis 
account for more than 111 million and 616 million cases of disease per year, respectively. 
Although mild diseases caused by S. pyogenes are seemingly benign, these infections 
impose considerable health and economic burdens worldwide, with the highest rate of 
incidence among children 5 to 15 years of age (1, 8). These infections can be easily treated 
with first-line b-lactam antibiotics (8), however, if left untreated or with penetration of the 
epithelial surface, S. pyogenes may also trigger a variety of severe invasive diseases. This 
includes bacteremia, necrotizing fasciitis and streptococcal toxic shock syndrome, among 
other less common clinical manifestations (9). 
 
Invasive S. pyogenes infections are often life-threatening and carry a high mortality rate 
(>50%) in both the developed and developing world (1, 9). Globally, invasive diseases 
affect over 18.1 million individuals, with an incidence of 1.78 million cases (8). In 
developed countries, the highest burden of GAS-related mortality results from invasive 
disease, despite the steady decline in incidence (9). While this may account for the greatest 
number of deaths in affluent countries, ~97% of the 660,000 estimated cases of invasive 
GAS infections occur in less developed countries, accounting for nearly 163,000 deaths 
each year. Of the cases identified, low- to middle-income areas within Sub-Saharan Africa 
and Asia, and indigenous-minority groups in the developed world, are predominately 
affected by invasive streptococcal diseases. Within these regions, ~29% of all bacteremia 
isolates in children are caused by GAS (8, 9). 
 
Acute rheumatic fever and its sequelae, rheumatic heart disease, continue to be the leading 
causes of GAS-associated morbidity and mortality worldwide. With an estimated 15.6 
million people living with rheumatic heart disease, ~233,000 premature deaths, and another 
116,000 deaths each year from additional complications, rheumatic heart disease is 
recognized as a global health problem (8). Studies have identified overcrowding and 
poverty as risk factors of acute rheumatic fever, with ~60% of cases leading to rheumatic 
heart disease. In endemic regions such as Africa, the Pacific, Latin America, the Middle 
East, Asia, and indigenous populations of Australia and New Zealand, children, young 
adults and pregnant women are particularly vulnerable to acute rheumatic fever and 
rheumatic heart disease. To reduce the risk of acute rheumatic fever and mitigate valve 
  
4 
damage, prophylactic antibiotic treatment for GAS pharyngitis is recognized as the primary 
prevention strategy. However, if acute rheumatic fever progresses to rheumatic heart 
disease, surgical intervention may be required (8, 10). 
 
The global distribution of S. pyogenes contributes to an immense burden of human illness. 
However, prevalence, incidence, and mortality of disease are unequally distributed 
throughout the world. Studies suggest that disease is strongly correlated with seasonal 
variability, geographic location, and socio-economic status. Therefore, developing 
countries are disproportionately impacted by GAS due to poor sanitary standards and 
minimal access to healthcare and resources (8), making it increasingly difficult to establish 
the true burden of GAS disease. Without accurate high-quality data from low-resource 
settings where the burden of disease is greatest, we are unable to design appropriate 
prevention and treatment strategies to control S. pyogenes outbreaks and ultimately reduce 
the global burden of streptococcal disease (8, 10).  
 
1.3 Asymptomatic carriage 
The GAS carrier state is described as having a prolonged bacterial presence that does not 
appear to be causing overt signs of disease. Under these circumstances, a physical 
examination – swab of the posterior pharynx – and serological testing have been used to 
identify the presence of S. pyogenes. If rapid diagnostic testing and/or throat culture for S. 
pyogenes are positive without the classical clinical signs and symptoms of acute pharyngitis 
(i.e., sore throat, inflammation of tonsils, fever), individuals are considered asymptomatic 
carriers (11, 12).  
 
GAS primarily colonizes the naso- and oropharynx in the human host (13). However, it is 
unclear whether individual genetic factors and type-specific bacterial characteristics 
influence host-pathogen interactions that contribute to streptococcal colonization. 
Therefore, despite what we know about S. pyogenes, the predominant and benign 
asymptomatic state is poorly understood. (11, 13, 14).  
 
Many studies suggest that carriage within the human population is dependent on a number 
of factors: age-group, geography, climate, repeated environmental contact and seasonal 
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trends (5). For example, a 4-year longitudinal study in Pittsburgh on school-aged children 
5 to 15 years of age isolated S. pyogenes from 27% to 32% of the cohort over the course of 
one school year. In this study, asymptomatic children typically carried a single emm type 
that persisted between 3 to 123 weeks, and those that sporadically cleared GAS were more 
likely to acquire recurrent infections with a different emm type and demonstrate new 
clinical symptoms (12). A meta-analysis on the prevalence and carriage of GAS in the 
United States in the past 35 years found that 37% of children under 18 years of age 
presenting signs of bacterial pharyngitis were positive for S. pyogenes. However, only 12% 
of children surveyed were considered asymptomatic carriers of GAS (15). In Melbourne, 
Australia, one study reported GAS carriage rates between 0% to 10% for children under 
18. These findings were similar to the carriage rates of healthy children surveyed in both 
Croatia (6%) and Iran (11%) (16, 17), but varied greatly from a study in Victoria, Australia, 
which previously described carriage rates as high as 16% due to seasonal and geographic 
variability (18, 19). In a family-based study in Australia, the incidence of S. pyogenes 
infection increased with household exposure to primary cases of GAS pharyngitis. It was 
determined that household contacts were almost twice (43%) as likely to acquire secondary 
GAS infections (20). This association had been previously noted by Schwartz et al. (21), 
who reported that ~25% of household contacts of children with streptococcal pharyngitis 
were asymptomatic but positive for GAS. Therefore, the carrier state of GAS is both 
complex and very common among school aged-children, but despite decades of research, 
the underlying molecular mechanisms contributing to this dominant state remain an 
enigma.  
 
1.4 Mechanisms of colonization and disease  
1.4.1 Mechanisms of adhesion 
The nasopharynx and the skin are major sites of colonization for GAS. In order to cause 
infection or establish asymptomatic colonization, S. pyogenes requires strong adherence 
mechanisms to subvert a variety of mechanical, chemical, and biological barriers present 
in humans. Surface adhesins allow S. pyogenes to bind to specific receptors on host cells, 
penetrate intact barriers, and colonize in unfavourable environments with low pH and 
moisture content, and among antimicrobial compounds (i.e., defensins, lysozymes) highly 
prevalent on epidermal and mucosal surfaces (1, 22). While many adhesions have been 
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described in the literature, expression of streptococcal adhesions are tissue-specific. 
Therefore, although S. pyogenes utilizes a multi-adhesin approach that is often functionally 
redundant to colonize host cells, different surface adhesins provide selectivity for the 
adherence of different streptococcal strains (1, 23). 
 
1.4.1.1 LTA 
The adhesion process for GAS is often described using a two-step process. The first step 
of adhesion involves a relatively weak hydrophobic interaction mediated by lipoteichoic 
acid (LTA). This glycolipid moiety is a major cell surface component of Gram-positive 
bacteria that plays an important role in adhesion and biofilm formation. In this model, LTA 
allows S. pyogenes to overcome electrostatic repulsion and attach to a number of cell types 
including buccal epithelial cells, HEp-2 cells, and polymorphonuclear cells, lymphocytes, 
and erythrocytes (24–26). To mediate adherence of S. pyogenes to the epithelial layer, LTA 
binds to its cognate host-receptor, fibronectin, forming a complex with other streptococcal 
surface proteins (1, 26, 27). This complex stimulates multiple high-affinity, tissue-specific 
interactions formed by other adhesins, including M protein, the pili, and fibronectin-
binding proteins (1, 5, 27, 28).  
 
1.4.1.2 M protein 
The M protein, encoded by the emm gene, is one of the best studied surface molecules of 
S. pyogenes (27). Composed of typically four repeat regions designated A through D, this 
multi-domain alpha-helical coiled-coil structure extends as hair-like projections from the 
surface of the bacteria. With the conserved C-terminus region anchored to the cell wall and 
the hypervariable N-termini protruding from the surface, the M protein is able to adhere to 
a number of eukaryotic receptors found on skin and mucosal surfaces (23, 27, 29).  
 
Recognized for its prominent role in immune evasion and adhesion, the M protein is 
considered a major virulence factor of S. pyogenes. To subvert the innate immune response, 
the streptococcal M proteins possess anti-phagocytic properties rendering the bacteria 
resistant to opsonization and neutrophil recognition (1, 5). However, the molecular 
mechanisms involved in adherence are less understood. Much of the evidence suggests that 
different M proteins bind to particular eukaryotic cells to mediate adherence. For example, 
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some of the earliest work demonstrates that the M protein is required for binding to human 
buccal cells (30). Alternatively, work by Courtney and colleagues (25) has showed that 
certain serotypes including M1, M5, M6, and M24 are not involved in attachment to buccal 
epithelial cells, but are required for adherence to the human laryngeal epithelial cell line 
HEp-2. Other studies have found that specific parental M types attached to human 
pharyngeal epithelial cells in greater numbers than both buccal or tongue epithelial cells. 
Compared to the parental strains, the M protein-deficient strains in this study were unable 
to efficiently bind epithelial cells, demonstrating the role of M protein in throat-mediated 
adherence (31).  
 
Based on these findings, it is evident that the streptococcal M proteins attach selectively to 
host receptors on specific cell types. Therefore, the role of the M protein in mediating 
adherence to eukaryotic cells is dependent on the M-serotype and tissue tropism. There are 
four different subfamilies of emm genes that may play a partial role in determining tissue 
tropism (1, 23, 27, 28, 32, 33). The chromosomal arrangement of the emm genes are divided 
into five distinct patterns denoted A to E and are distinguished by the peptidoglycan-
spanning domain. Strains with patterns A to C have tissue site preference for the pharynx; 
whereas strains with pattern D are recovered more often from cases of impetigo. Unlike 
patterns A to D, strains with pattern E are not tissue specific, and have been isolated from 
both the skin and the pharynx (32).  
 
Much of the work done on M proteins suggests that multiple membrane bound proteins 
may serve as cellular receptors for the M protein ligand (1, 27). There have been reports of 
streptococcal M proteins binding to: fibronectin on the surface of oropharyngeal cells (34); 
membrane cofactor protein CD46 on epidermal keratinocytes (35); sialic acid-containing 
receptors on mucin lining the pharyngeal epithelium (36); and fucose-containing 
oligosaccharides found on cultured HEp-2 cells (37). Despite these findings, there remains 
a lot of controversy over the M protein and its role in S. pyogenes adherence (27).  
 
1.4.1.3 Pili  
Gram-positive and Gram-negative bacteria are decorated with long pilus-like structures 
protruding from the bacterial cell wall (38, 39). These surface appendages are encoded on 
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a pathogenicity island known as the fibronectin-binding, collagen-binding, T-antigen 
(FCT) region, and are described as vital structures for adherence, biofilm formation, and 
virulence in group A and group B streptococci. Many studies demonstrate that the GAS 
pilus mediates efficient attachment to multiple human cell types, including primary and 
cultured keratinocytes, as well as epithelial cells derived from human tonsils (40); the skin 
(41), and the pharynx (38). To date, there have been nine different FCT islands identified. 
Although these islands are highly variable in S. pyogenes, the structural integrity of the 
pilus is highly conserved across serotypes. Pilus-like appendages in S. pyogenes are 
composed of polymerized backbone protein covalently attached to one or two ancillary 
protein caps. These structural subunits are assembled by pili-associated sortase enzymes 
which are also encoded in the FCT operon (5, 27, 38). Despite our understanding of the 
structure and assembly of the pilus, the complex processes involved in pili-mediated 
adherence and colonization have yet to be elucidated (38).  
 
1.4.1.4 Hyaluronic acid capsule 
S. pyogenes produces a capsule comprised of hyaluronic acid; a linear polymer of N-
acetylglucosamine and glucuronic acid, that yields distinct mucoid colonies when grown 
on blood agar. Encoded by the 4.2 kb has operon, the hyaluronic acid capsule is highly 
conserved across most clinical isolates of GAS, except M4 and M22 serotypes, which lack 
the capsular genes and in turn produce hyaluronidase. As a major component of mammalian 
tissue, the hyaluronic acid polysaccharide produced by S. pyogenes is structurally identical, 
and therefore, poorly immunogenic in the human host (5, 42, 43). 
 
Hyaluronic acid capsule production varies among different strains of GAS. In S. pyogenes, 
capsule biosynthesis is regulated by growth conditions and in response to changes in the 
host environment (5). Testing in vitro has demonstrated that capsule production is rapidly 
induced during early- to mid-exponential phase (44). These observations are further 
supported in vivo. During invasive infection in the peritoneum of mice, and in pharyngeal 
colonization using a non-human primate model, high levels of capsule gene expression 
were induced within 1-2 h after the introduction of GAS. This suggests that the hyaluronic 
acid capsule is essential during the initial stages of colonization (45). Although it is widely 
believed that the capsule allows GAS to persist in the pharynx, the role of the hyaluronic 
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acid capsule in mediating adherence remains controversial. Many studies have 
demonstrated that GAS attachment to epithelial cells occurs through binding to the cell 
surface ligand CD44 (46–48). While this may serve as a critical point of attachment to 
pharyngeal and epidermal cells, there is evidence to suggest that encapsulated strains of 
GAS bind the epithelium with similar (49), and in some cases, reduced efficiency to 
acapsular strains (46, 48). Despite these findings, encapsulated streptococcal strains seem 
to provide a greater advantage in infection models. In both murine and primate models of 
pharyngeal colonization, capsule-deficient strains of GAS were unable to persist in the 
pharynx, and cleared rapidly by host phagocytes when compared to the wild-type strains 
(49, 50). Therefore, the structural and anti-phagocytic properties of the capsule allow S. 
pyogenes to circumvent the host immune response, demonstrating a critical role for the 
hyaluronic acid capsule in GAS virulence and colonization. 
 
1.4.2 Secreted virulence factors  
S. pyogenes secretes a number of extracellular proteins that play an important role in 
colonization and the initiation of disease. These secreted toxins are considered virulence 
factors and are responsible for a diverse range of functions essential to the success of the 
pathogen. This impressive arsenal of virulence factors includes: proteinases, DNases, 
complement-inhibitors, plasminogen-binding proteins, hemolysins, superantigens, and 
bacteriocins, which allow S. pyogenes to facilitate invasion, resist host defence 
mechanisms, and outcompete endogenous microbiota within a given biological niche (1, 
28, 51). Although each of these virulence factors plays a critical role disease pathogenesis, 
this chapter will review the hemolysins, superantigens, and bacteriocins secreted by S. 
pyogenes during infection.  
 
1.4.2.1 Hemolysins 
S. pyogenes secretes two major extracellular toxins called the streptococcal cytolysins, 
streptolysin O (SLO) and streptolysin S (SLS). These potent pore-forming toxins target a 
number of eukaryotic cells (51–53), which contribute to GAS virulence through a variety 
of poorly understood mechanisms (51, 54, 55). The first of these hemolysins, SLO, is an 
oxygen-labile and cholesterol-dependent cytolysin capable of forming large pores in the 
host cell membrane to induce apoptosis (54–56). In a pore-dependent manner (57), SLO 
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enhances GAS pathogenicity through the translocation of NAD+-glycohydrolase 
(NADase). This toxin, which is co-expressed with SLO, is delivered to the cytoplasm of 
host cells through a process known as cytolysin-mediated translocation, where it functions 
to modulate host cell signalling pathways. SLO-mediated delivery of NADase interferes 
with cellular repair mechanisms and prevents acidification of the phagolysosome, thereby 
blocking internalization and destruction of the invading bacterium. Murine models of GAS 
infection demonstrate that in the absence of SLO, S. pyogenes is significantly impaired in 
its ability to survive in macrophages. These findings suggest that together, SLO and 
NADase play a critical role in enhancing intracellular survival and proliferation of GAS 
(52, 58–60).  
 
In addition to SLO, S. pyogenes produces a second hemolysin known as SLS. This oxygen-
stable, non-immunogenic toxin is encoded by the nine-gene sag operon, which is 
remarkably similar to the genetic organization of bacteriocin-gene clusters encoded by 
other bacteria (56, 61). SLS is secreted by many strains of S. pyogenes and is responsible 
for the distinct b-hemolytic phenotype surrounding GAS colonies grown on blood agar. 
Similar to SLO, SLS possesses a broad cytotoxic spectrum that targets erythrocytes (62, 
63), leukocytes (53), and platelets (64) by the formation of a transmembrane pore that 
disrupts osmotic balance, resulting in cell lysis (63). However, recent studies suggest a 
more complex role for SLS in facilitating GAS pathogenesis. Flaherty et al. (65) 
demonstrate that SLS is capable of manipulating host cell signalling pathways, thereby 
triggering a rapid proinflammatory response that leads to programmed cell death of 
epithelial cells. Other groups have reported SLS-induced apoptosis of immune cells 
through caspase-dependent and independent mechanisms (65, 66). These processes 
implicate SLS as a critical factor for innate immune evasion by GAS (67–69). Further 
evidence suggests that SLS-deficient mutants are attenuated in their ability to induce cell 
death during infection (68), and are significantly less virulent than their wild-type 
counterparts in vivo (54, 65, 70). 
 
1.4.2.2 Superantigens  
Streptococcal superantigens represent a large fraction of the family of mitogenic exotoxins 
that are capable of inducing an exaggerated T lymphocyte response (71, 72). These highly 
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potent pyrogens are best studied in Staphylococcus aureus and S. pyogenes, but are also 
present in other bacterial pathogens, including group C and G streptococci, coagulase-
negative staphylococci, Mycoplasma arthritidis and Yersinia pseudotuberculosis. 
Together, the streptococcal and staphylococcal superantigens comprise a group of 
structurally and functionally-related toxins recognized for their key role in the pathogenesis 
of toxic shock syndrome (71–76).  
 
Superantigens have a remarkable ability to simultaneously bind host major 
histocompatibility complex (MHC) II molecules on antigen presenting cells and the b-chain 
variable domain (Vb) on T cell receptors of CD4+ and CD8+ T cells in a peptide-
independent manner. Unlike conventional T cell activation, superantigens bind outside the 
designated peptide-binding groove and are not restricted by polymorphic determinants of 
MHC class II. Therefore, superantigens can bind to multiple Vb chains in the T cell 
repertoire and stimulate up to 25% of an individual’s T cell population, compared to 
classical peptide presentation which activates only one in 105 to 106 naïve T cells (73, 75). 
Recent evidence suggests that a second signalling molecule may also be required for T cell 
activation by superantigens. Induction of human inflammatory cytokine gene expression 
may require direct superantigen binding to co-stimulatory molecule CD28 (77) and its co-
ligand B7-2 (CD86) (78), which are constitutively expressed on T cells and antigen 
presenting cells, respectively. As a critical component of the immune response, the 
superantigen-CD28-B7-2 interaction drives a hyper-active T helper 1 (Th1) response (77, 
79) characterized by the overproduction of inflammatory cytokines, including tumor 
necrosis factor a (TNF-a), interleukin (IL)-1b, IL-6, IL-2, and interferon (IFN)-g (23, 73, 
78, 80).  
 
Evidence suggests that other factors may influence the T cell response to superantigens. 
The most important consideration is the strength and stability of the immune complex 
(superantigen-MHC-T cell interaction). Although all complex formations are able to 
potently activate T lymphocytes, different superantigens have unique preference or affinity 
towards different binding sites, which may affect the proliferation response. For example, 
nine out of fourteen streptococcal superantigens bind the MHC II b-chain in a zinc-
dependent manner, which is referred to as the “high-affinity” binding site. In contrast, the 
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MHC class II invariant a-chain is recognized as a “generic” or “low-affinity” binding site 
for streptococcal superantigens (73). Furthermore, superantigens preferentially bind to 
human leukocyte antigens (HLA) class II molecules, indicating that HLA polymorphisms 
may also affect the binding affinity of the immune complex. High-affinity interactions 
between the superantigen, MHC, and T cell receptor are thought to enhance the potency of 
the resulting inflammatory response (73, 75, 81).  
 
Although superantigens have been implicated in the development of severe streptococcal 
diseases such as necrotizing fasciitis and toxic shock syndrome (73, 79), the evolutionary 
advantage of superantigens is only now beginning to be understood. Recent evidence from 
our laboratory has demonstrated that these exotoxins play a critical role in the initial stages 
of colonization by S. pyogenes (82, 83). Using a murine model of acute nasopharyngeal 
infection adapted from Park et al. (84), we show that expression of human MHC class II 
molecules HLA-DR4/DQ8 and the streptococcal pyrogenic exotoxin A (SpeA) results in a 
robust infection phenotype observed in transgenic mice compared to wild-type C57BL/6 
mice (82). We also demonstrated that vaccination with a toxoid SpeA molecule reduced 
the bacterial burden and provided antibody-mediated protection against subsequent 
nasopharyngeal challenge with wild-type S. pyogenes (82, 83). Moreover, these 
immunization experiments show that in the absence of Vb-specific CD4+ and CD8+ T cells, 
S. pyogenes is unable to drive the proinflammatory environment necessary for 
nasopharyngeal colonization. Therefore, there is strong evidence to suggest that 1) bacterial 
superantigens and host MHC II molecules are required for acute infection in the 
nasopharynx (82) and 2) superantigens utilize Vb-specific T cells to remodel the 
nasopharyngeal environment to establish colonization (83).  
 
1.4.2.3 Bacteriocins  
Niche competition is often driven by the secretion of potent antimicrobial toxins called 
bacteriocins. Bacteriocins are ribosomally-synthesized polypeptides produced by both 
Gram-positive and Gram-negative bacteria, which inhibit the growth of close genetic 
relatives or non-related (broad spectrum) bacteria within an ecological niche. Due to the 
diverse and abundant nature of bacteriocins, families are often grouped by their mode of 
action, mechanism of secretion, structure, genetics, immunity mechanism, and microbial 
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targets. In complex microbial environments such as the skin, gastrointestinal tract, and the 
nasopharynx, bacteriocins are thought to be used to eliminate other bacterial species 
competing for the same limited space and resources. Importantly, bacteriocin-producing 
strains encode additional genes which provide protection against their own antimicrobial 
peptides (85, 86).  
 
Gram-positive bacteriocins can be classified into four distinct groups based on the 
classification system first proposed by Klaenhammer (87) and illustrated in Figure 1. 
Although this may be the most accepted classification scheme, only three groups are 
universally acknowledged in literature. Due to the increasing body of knowledge on the 
structure and chemistry of bacteriocins, and inconsistency in the parameters used for 
classification, there remains some criticism of the current classification approach (88). 
Despite these discrepancies, all established classes will be reviewed: (I) Lantibiotics are 
small (<5 kDa) membrane-active antimicrobial peptides that derive their name from the 
addition of post-translationally modified amino acids such as lanthionine and b-
methyllanthionine. Depending on their molecular structure, these peptides are grouped as 
linear (type A) or globular (type B) lantibiotics. (II) Class II bacteriocins are small (<10 
kDa), unmodified, heat-stable toxins that permeabilize target-cell membranes through an 
influx of ions. In their precursor form, class II bacteriocins contain a double-glycine N-
terminal leader motif, which is a hallmark of class II secretion. This motif is cleaved by a 
dedicated ATP binding cassette (ABC)-transporter to produce the active secreted form. 
Class II bacteriocins can also be structurally divided into multiple subclasses, including: 
type-IIa (pediocin-like peptides), -IIb (two-component peptides), and -IIc (cyclic peptides). 
Other subdivisions have also been considered due to differences in peptide structure. (III) 
The third class of bacteriocins, recognized as the group of large (>30 kDa) heat-labile 
proteins, possess a lytic- (IIIa) or non-lytic (IIIb) mode of action. Due to their enzymatic 
nature, they are sometimes referred to as bacteriolysins (85, 87, 88). Lastly, a fourth class 
of bacteriocins has also been proposed (87, 89, 90). This group consists of antimicrobial 
peptides containing lipid or carbohydrate moieties. For example, bacteriocins with post-
translational cysteine S-glycosylation modification have been identified in Lactobacillus 
plantarum (90). However, due to difficulties in peptide purification, class IV bacteriocins 

















Figure 1. Classification of bacteriocins produced by Gram-positive bacteria. 
There are four classes of Gram-positive bacteriocins based on the original classification 
system proposed by Klaenhammer (87). Class IV bacteriocins are typically omitted from 











































action, Figure 2 provides a summary of Gram-bacteriocin activity (91). 
 
1.5 S. pyogenes bacteriocins 
Many members of the Streptococcus genus produce bacteriocins to mediate intra- and 
interspecies colonization in a given biological niche. Examples include pathogenic and 
benign streptococci such as Streptococcus pneumoniae and Streptococcus salivarius that 
utilize bacteriocins to eliminate bacterial competitors within the oral mucosa (92). 
Although various streptococci have evolved mechanisms to compete for niche space, the 
bacteriocins produced by S. pyogenes are poorly characterized in comparison. 
 
Antimicrobial activity by GAS was first observed in 1971 by the S. pyogenes strain FF22 
(93). The name, streptococcin A-FF22 (SA-FF22), was ascribed to the 26-amino acid 
bacteriocin, which was later classified as a type A lantibiotic for its similarity to the 
prototypical lantibiotic nisin produced by Lactococcus lactis (94). SA-FF22 is 
predominately active against other streptococci, and a wide range of Gram-positive bacteria 
including L. lactis, Bacillus cereus, and Bacillus subtilis (92–94). However, unlike other 
linear lantibiotics, SA-FF22 possesses unique structural (i.e., different proteolytic cleavage 
site) and regulatory components (i.e., two-component system [TCS]) that are essential for 
bacteriocin production (95). 
 
Streptin is class A lantibiotic originally isolated and characterized from S. pyogenes. 
Although the streptin locus is highly conserved across different streptococci, only 10% of 
S. pyogenes strains produce a biologically active form of streptin. There are two major 
forms of streptin with comparable inhibitory and autoinducing properties. The fully 
processed form of streptin, referred to as streptin 1, is a 23-amino acid peptide with a broad 
activity spectrum against streptococci. The second form of the peptide – streptin 2 – has 
similar antimicrobial activity, yet contains three additional amino acids (TPY) at the N-
terminal region (92, 96, 97). A comparison of the biosynthetic gene clusters in nisin and 
subtilin demonstrate high sequence homology to the structural gene of streptin (srtA) 
among other open reading frames for streptin immunity (srtI), regulation (srtR/K), transport 
(srtT), prepeptide modification (srtC/B), and self-protection (srtF/E/G). The arrangement 














Figure 2. Mode of action of Gram-positive bacteriocins. 
Bacteriocins produced by Gram-positive bacteria can be grouped into three distinct classes 
based on their mode of action. Some members of class I (or lantibiotic) bacteriocins have 
a dual mode of action. They typically function as pore-forming toxins, but in some cases, 
they may also prevent correct cell wall synthesis. Both mechanisms involve an interaction 
with lipid II molecules that leads to cell lysis. Class II (small, unmodified peptides) 
bacteriocins have an amphiphilic helical structure that allows them to insert into the cell 
membrane of target cells. This process disrupts the membrane potential, which also results 
in cell lysis. The third class of bacteriocins, referred to as bacteriolysins, directly degrades 




































protease for prepeptide processing, removal of the leader sequence in streptin is dependent 
on the general streptococcal cysteine protease SpeB (96). 
 
The only non-lytic and plasmid-borne bacteriocin system identified in S. pyogenes is the 
large 179-amino acid polypeptide streptococcin A-M57 (SA-M57). This class III 
bacteriocin system derives its name from the unique association to one serotype-specific 
lineage of S. pyogenes, M57 (98, 99). SA-M57 possesses a particularly unusual activity 
spectra that targets a diverse range of non-streptococcal Gram-positive bacteria, including 
Micrococcus luteus, L. lactis, Bacillus megaterium, Staphylococcus simulans, and all tested 
species of Listeria. Although the exact mechanism of killing remains unclear, SA-M57 
secretion is thought to occur through the Sec-dependent transport pathway (85, 99).  
 
Recent findings from our laboratory suggest that S. pyogenes also produces two class IIb 
bacteriocin systems termed the S. pyogenes bacteriocins (spb) which have not been 
previously characterized. To avoid confusion between the two systems, we designated the 
open reading frames of the first system as the spbM and spbN genes, and those of the second 
putative system as the spbJ and spbK genes (100; unpublished data) (Figure 3). Although 
the latter system has not been explored in detail, we demonstrate through recombinant 
expression of the SpbM and SpbN peptides that Spb possesses broad spectrum activity 
against other group A and G streptococci, and Gram-positive bacteria such as M. luteus and 
L. lactis. Further analysis of the structural genes spbM and spbN reveal that these peptides 
are homologous to the bacteriocin-like peptide (Blp) M and N in S. pneumoniae, 
respectively (100). These peptides can be found in all sequenced strains of S. pneumoniae 
and may contribute to nasopharyngeal colonization (101, 102). Similarly, most sequenced 
strains of S. pyogenes contain complete sequences for spbM and spbN, suggesting that the 
Spb locus provides a potential advantage during colonization (100). Since there are no prior 
reports of functional two-peptide bacteriocin systems in S. pyogenes, the next section will 







1.5.1 Class IIb bacteriocins 
Class IIb bacteriocins consist of two different peptides that function together as a single 
antimicrobial unit. Although the individual peptides may display low antimicrobial 
properties, the production of two complementary peptides in equal amounts is required to 
induce optimal activity (103, 104). The structural genes encoding the two peptides are 
adjacent in the operon and found next to the immunity gene –which offers protection from 
the bacteriocins in an unknown mechanism – and genes for bacteriocin export. In their 
immature form, each peptide is synthesized with a double-glycine N-terminal leader 
sequence ~15-30 amino acids in size. This motif is cleaved off at the C-terminal side by a 
dedicated ABC-transporter, resulting in export of the mature peptides out of the cell. 
Together, the two peptides – often referred to as a and b – form a transmembrane helical- 
helical structure that penetrates into the hydrophobic core of target cell membranes. 
Through the highly conserved GxxxG-motifs present on the peptides, the double helix 
structure remains stabilized in a parallel orientation, which allows for formation of the pore 
(103, 105).  
 
Aside from their unique structural features, class IIb bacteriocins have pore-forming 
abilities that differ in specificity. With few exceptions, the members of this group possess 
a relatively narrow inhibitory spectrum that is limited to their own bacterial species. This 
specificity is predominately determined by the N-terminal amino acid sequence of the b-
peptide, and is displayed with respect to the molecules conducted across the cell membrane 
(104, 106). For example, lactococcin G produced by L. lactis disrupts the membrane 
potential by increasing permeability to a number of monovalent cations such as sodium, 
potassium, and choline, with the exception of protons. But it appears that other two-peptide 
systems, such as plantaricin E/F and plantaricin J/K produced by L. plantarum, transport 
monovalent ions, including protons, efficiently across the cell membrane to induce 
membrane-leakage and cell death (105). 
 
To regulate bacteriocin expression, most two-peptide systems employ a sophisticated 
intracellular communication system known as quorum-sensing. Quorum-sensing is 
bacterial cell-to-cell communication that relies on changes in cell density to regulate 















Figure 3. Map of sil-spb loci in the M18 serotype S. pyogenes strain MGAS8232. 
Open reading frame maps of the Streptococcus invasion locus (sil) and the Streptococcus 
pyogenes bacteriocin (spb) operons in S. pyogenes MGAS8232 (accession: NC_003485.1). 
The spbJK locus, located downstream of the sil operon, encodes the bacteriocin structural 
genes, spbJ and spbK, and an associated immunity protein, spbL, for degradation of the 
bacteriocins through a putative membrane-bound metalloprotease. The spbMN locus, 
located upstream of the sil operon, encodes two adjacent bacteriocin genes, spbM and spbN, 

















































of three components: an intracellular response regulator (RR), a membrane-associated 
histidine protein kinase (HK), and a peptide pheromone (104, 105). Peptide pheromones, 
also referred to as induction peptides, are small, typically unmodified peptides that are 
highly related to class IIb bacteriocins in structure. They contain the same N-terminal signal 
motif that is recognized by the bacteriocin export machinery during secretion. Once the 
inducing peptide reaches a threshold concentration, the bacteria respond accordingly to 
collectively regulate gene expression within their environment (107). Therefore, signal 
transduction is initiated when the peptide pheromone interacts with the HK. This triggers a 
phosphorylation event of the RR that subsequently activates transcription of the 
bacteriocins and associated genes, as well as the induction peptide (104). After a certain 
amount of time, the genes are downregulated, resulting in the inactivation of quorum-
sensing based bacteriocin production (108). 
 
1.6 S. pyogenes metabolism  
Different sites of infection represent a nutritionally unique landscape for S. pyogenes that 
differ in carbohydrate availability and abundance. To thrive in these diverse 
microenvironments, S. pyogenes has adapted numerous pathways to generate energy in the 
cell and maintain metabolic fitness (109). While many pathways contribute to the success 
of S. pyogenes as a pathogen, this chapter will focus on carbohydrate metabolism with 
respect to glucose and lactose utilization. 
 
1.6.1 Glucose metabolism and transport 
Like most bacteria, the preferred carbohydrate source for S. pyogenes is glucose. In 
glucose-rich environments, S. pyogenes generates energy through the classical glycolytic 
pathway known as the Ebden-Meyerhof-Parnas (EMP) pathway. This pathway consists of 
twelve coupling enzymes that are activated by divalent cations such as magnesium (Mg2+) 
and manganese (Mn2+). Once activated, the enzymes bind to negatively-charged, high-
energy phosphorylated substrates to catabolize glucose into pyruvate. This conversion 
yields immediate energy in the form of two molecules of adenosine triphosphate (ATP) and 




While glucose may be the favoured substrate, S. pyogenes must adapt to specific nutritional 
microenvironments depending on the site of infection. For example, during colonization of 
the oral cavity or the skin where glucose is present in only scarce amounts, S. pyogenes 
must rely on alternative substrates and metabolic pathways to generate energy for growth 
and survival (109). However, in the presence of glucose, the genes responsible for 
catabolizing complex carbohydrates are repressed. This conserved regulatory phenomenon, 
referred to as carbohydrate catabolite repression (CCR), enables streptococci to cope with 
alternating periods of carbohydrate starvation and excess glucose availability by the 
differential regulation of genes (109, 110).  
 
In S. pyogenes, CCR is regulated by the phosphoenolpyruvate (PEP)-dependent 
phosphotransferase (PTS) system which catalyzes the uptake and transport of various 
carbohydrate sources though phosphorylation-dependent mechanisms. The PTS is 
composed of two cytoplasmic components, enzyme I (EI) and a histidine-containing 
phosphoryl carrier protein (HPr), in addition to one-membrane spanning protein known as 
the sugar-specific permease (EII) (109, 111, 112). Briefly, a phosphorylation cascade is 
initiated when the phosphoryl donor PEP phosphorylates a conserved histidine residue in 
EI. Phosphorylated EI then transfers the high-energy group to the His-15 site of HPr, which 
serves as an intermediate phosphoryl donor to the EIIA and EIIB domains of the sugar-
specific permease. In the final step, the phosphoryl group of EIIB is transferred to a cognate 
carbohydrate molecule bound to the membrane-spanning EIIC domain of the EII complex. 
The resulting phosphorylated carbohydrate is then released into the cytoplasm and 
processed as glycolytic intermediate (112). In addition to PEP-mediated phosphorylation 
of HPr, the phosphocarrier protein can also be phosphorylated by a HPr 
kinase/phosphorylase (HPrK/P) at an alternative site. Regulation of the HPrK/P is 
dependent on the concentrations of fructose 1,6-bisphosphate (FBP) and inorganic 
phosphate. In general, the kinase function of HPrK/P is induced in response to high levels 
of FBP. This results in phosphorylation of HPr at the Ser-46 residue, which is then able to 
interact with catabolite control protein A (CcpA). Together, the CcpA-HPrSer-46 dimer 
stimulates the repressor function of CCR in the presence of glucose by binding to specific 
catabolite responsive elements (cre) present upstream of catabolic genes. Over time, 
utilization of intracellular ATP and FBP leads to an increase in inorganic phosphate, which 
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modulates phosphatase activity of the HPrK/P enzyme. Therefore, alterations in the 
phosphorylated state of the PTS are dependent on the metabolic demands of the cell and 
the relative concentrations of FBP and inorganic phosphate (109, 112). 
 
1.6.2 Lactose metabolism and transport  
All strains of S. pyogenes possess two lac gene clusters designated lac.1 and lac.2 that 
encode components of the tagatose-6-phosphate pathway for lactose and galactose 
metabolism. These operons have likely evolved from gene duplication yet serve distinctly 
separate functions in S. pyogenes. The Lac.1 locus contains several truncated genes, making 
it unable to catabolize the appropriate sugars. It has instead adapted a novel regulatory role 
via LacD.1 as a transcriptional regulator of virulence genes, while maintaining its 
enzymatic aldolase capacity. In contrast, the Lac.2 operon encodes eight full-length genes 
dedicated for lactose and galactose utilization, but does not have any reported regulatory 
activity (113, 114). 
 
Lactose and galactose catabolism begin through PTS-mediated uptake and 
phosphorylation. Using the lactose-specific PTS transporter encoded by the lac.2 operon, 
exogenous lactose and galactose are released into the cytoplasm in the form of 
phosphorylated lactose, and subsequently broken down into either energy-rich glucose or 
galactose intermediates. The former molecule serves as a substrate for the canonical EMP 
pathway, while the latter molecule is channeled into the tagatose-6-phophate pathway. 
Following a series of catalytic events, tagatose bisphosphate aldolase (LacD.2) converts the 
galactose intermediate into two three-carbon sugars, glyceraldehyde-3-phosphate (G3P) 
and dihydroxyacetone phosphate (DHAP). These sugars are utilized through EMP pathway 
for the formation of pyruvate (109).  
 
1.7 Virulence gene regulators of S. pyogenes  
The ability of S. pyogenes to colonize and persist in multiple tissues is dependent on its 
capacity to adapt to a dynamic host environment. During infection, S. pyogenes regulates a 
varied repertoire of virulence factors to cope with changes in its microenvironment. The 
spatial and temporal expression of these virulence factors are controlled by a complex 
network of regulators that are capable of integrating environmental cues such as nutrient 
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availability, pH, osmolarity, temperature, with information on the pathogen’s own 
metabolic state, to determine the appropriate response (115). This highly coordinated 
response promotes nutrient acquisition and the evasion of host immune factors, which 
facilitates disease progression by S. pyogenes (115, 116).  
 
While S. pyogenes possesses 13 TCS and more than 100 stand-alone response regulators 
(28), the following section will explore a few of the best characterized virulence-associated 
transcriptional regulators of global gene expression.  
 
1.7.1 CovRS  
Two-component signal transduction systems in bacteria employ a common stimuli-
response coupling mechanism to sense and respond to changes in the external environment. 
This system is composed of two conserved components: a membrane-bound HK and a 
corresponding RR. The former consists of a sensor domain that monitors environmental 
stimuli, and a cytosolic kinase domain that serves to modulate activity of the HK. When a 
stimulus interacts with the sensor domain of the HK this triggers autophosphorylation of 
the cytosolic domain. The phosphoryl group is then transferred from the HK to the RR, 
which binds to DNA to elicit a cellular response (117).  
 
The control of virulence (CovRS) TCS in S. pyogenes serves to regulate genes associated 
with the general stress response. When cells are subjected to environmental stressors such 
as elevated temperature, environmental Mg2+, low pH, LL-37, and iron starvation, CovS 
signals for a change in the phosphorylation state of its cognate RR CovR (28, 118–120). 
While this mechanism is thought to enhance DNA binding and transcription of downstream 
effectors, it has been proposed that the non-phosphorylated state of CovR also regulates a 
specific subset of genes. Therefore, CovR acts as a global transcriptional repressor of 
virulence genes in both a phosphorylated and non-phosphorylated state (115). 
 
The covRS regulon modulates transcription of ~10-15% of genes in the S. pyogenes genome 
(121); many of these genes are essential for infection and evasion of the host immune 
response. Although this list is not exhaustive, CovRS has been characterized as a 
transcriptional repressor of virulence factors such as the hyaluronic acid capsule, 
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streptolysins, DNases, streptokinase, and immunoglobulin (Ig)-degrading enzymes. While 
CovR functions primarily as a global repressor of virulence genes, it also acts as a 
transcriptional activator of speB cysteine protease expression (28, 115). 
 
Spontaneous mutations that inactivate either CovR or CovS enhance the virulence of this 
pathogen. In murine models of skin and soft tissue infection, mutations in the covRS genes 
correlate to development of severe invasive disease by S. pyogenes. This hypervirulent 
phenotype is characterized by an increase in the size and abundance of necrotic lesions, 
which results from overexpression of virulence factors (i.e., capsule, C5a peptidase, DNase 
Sda1) and decreased production of SpeB (28, 122–124). This renders covRS mutants highly 
resistant to phagocytosis and neutrophil-mediated killing (28, 124).  
 
1.7.2 Mga 
One of the best-characterized stand-alone regulators in S. pyogenes is Mga (115). Mga is a 
global response regulator that controls expression of multiple virulence genes involved in 
colonization (M-protein, M-like proteins, and fibronectin- and collagen-binding proteins) 
and immune evasion (C5a peptidase, complement inhibitors, and Ig-binding proteins). The 
mga regulon is activated during the exponential phase of growth, and in response to 
elevated CO2, increased temperature, and iron-limiting conditions (125–127). Under these 
growth conditions, Mga binds to upstream promoter sites of its “core” gene targets and its 
own encoding gene to upregulate transcription (128). In addition, indirect regulation by 
Mga may also alter expression of other virulence gene targets, including the hyaluronic 
acid capsule, SpeB, and genes involved in carbohydrate metabolism (28, 115).  
 
All GAS isolates carry either one of two allelic variations of the mga gene which give rise 
to throat (mga-1) or skin/non-specific (mga-2) infections by S. pyogenes. To adapt to such 
distinct microenvironments there are strain-specific differences in the regulation of Mga 
and its associated gene targets. This is considered a major driving force of tissue tropism 
(129). Furthermore, recent studies demonstrate that there is a direct link between 
carbohydrate utilization and Mga-dependent expression of virulence genes in S. pyogenes. 
In the mga operon, there are two PTS-regulatory domains that may be phosphorylated by 
the PTS. Mga appears to be phosphorylated in a carbohydrate-deficient state, suggesting 
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that Mga and its associated adherence factors are preferentially downregulated to promote 
tissue dissemination. However, in a carbohydrate-rich environment, mga is not 
phosphorylated and able to upregulate factors that promote colonization. Therefore, 
virulence factor gene expression by Mga is regulated in a temporal fashion that is coupled 
to nutrient availability (28, 130).  
 
1.7.3 CcpA 
In S. pyogenes, CCR is predominately controlled by the catabolite response regulator CcpA. 
CcpA serves to regulate activity of the PTS, and expression of several key virulence factors 
in a carbohydrate-dependent manner. At high intracellular concentrations of glycolytic 
intermediates such as FBP and inorganic phosphate, HPr interacts with CcpA to form a 
dimer. In its active form, CcpA binds to cre sites located in the promoter region of catabolic 
operons to repress transcription of alternative carbohydrate utilization genes [refer to 
section 1.6.1 for more detail] (115). 
 
Global transcriptional analyses of S. pyogenes have identified CcpA as an important 
regulator of virulence gene expression. It controls expression of many glucose-related 
virulence genes in a growth-phase dependent manner. While many of these virulence genes 
(speB [encoding the cysteine protease], sagA [for streptolysin S production], and cfa 
[encoding CAMP factor]) are linked to carbohydrate availability, a specific subset of CcpA 
gene targets are regulated independently of glucose. This suggests that multiple catabolite-
sensing pathways likely contribute to the global regulation of virulence factors in S. 
pyogenes (110, 131). Furthermore, it has been shown that loss of ccpA attenuates virulence 
in murine models of skin ulcers (110), oropharynx colonization, and invasive 
intraperitoneal infection (132). 
 
1.7.4 LacD.1 
LacD.1 was initially identified as a global regulator of virulence gene expression for its role 
in negative regulation of the secreted SpeB cysteine protease. Global profiling of the S. 
pyogenes transcriptome has demonstrated that LacD.1 represses SpeB expression in 
response to pH levels above 6.5, high salt concentrations, and carbohydrate availability 
(114). As mentioned previously, LacD.1 and its paralogous counterpart, LacD.2, possess 
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aldolase activity to metabolize lactose and galactose. However, LacD.1 has a unique 
regulatory role that has been adapted for virulence gene expression [refer to section 1.6.2 
for more detail] (113, 114).  
 
The mechanism by which LacD.1 regulates virulence gene expression in S. pyogenes is 
poorly understood (110). Regulation appears to function independently of LacD.1 catalytic 
activity but requires binding to glycolytic substrates, G3P and DHAP. Therefore, LacD.1-
mediated regulation is likely coupled to nutrient availability (110, 114). To validate this 
hypothesis, the contribution of LacD.1 on CCR was explored with respect to glucose 
utilization. Analyses have revealed that 15% of genes in S. pyogenes are altered in response 
to glucose, and together, CcpA and LacD.1 may control of up to 60% of this subset in 
various combinations. Regulation of affected virulence genes can occur through CcpA- and 
LacD.1-independent mechanisms (for example, CcpA alone regulates lctO [encoding 
lactate oxidase]), co-regulation (speB and ackA [encoding a putative arginine deaminase]), 
and through pathways independent of glucose (ackA regulation by CcpA). These findings 
demonstrate that differential expression of virulence genes requires the integration of 
temporal and environmental cues from numerous catabolite-sensing pathways during 
infection (110, 131).  
 
1.7.5 Sil  
A peptide-based quorum sensing system designated the streptococcal invasion locus (sil) 
has been identified in ~18% of S. pyogenes strains. Of these strains, many harbor mutations 
that render the Sil system non-functional (115, 133). However, in the M14 serotype S. 
pyogenes strain JS95 isolated from patient with necrotizing fasciitis, Sil was discovered as 
a key component of virulence. In this strain, Sil is associated with rapid GAS dissemination 
and invasion in a murine model of human soft-tissue infection. Other findings suggest that 
Sil mediates DNA transfer between different M-types (134).  
 
The genetic organization of sil resembles two separate regulatory networks used to activate 
competence (com) and bacteriocin production (blp) in S. pneumoniae (135). It contains six 
genes that encode a TCS (silA/B), an ABC transporter (silD/E), and two signalling peptides 
(silCR and silC) which form a novel regulatory circuit that controls the transcription of sil 
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(134, 136) (refer to Figure 3). Interestingly, this signal peptide can be sensed across 
different streptococci, which suggests a unique role for sil in facilitating colonization (135).  
 
Activation of sil plays a critical role in GAS adherence and competition during infection. 
Recent work has demonstrated that SLO- and SLS-mediated membrane damage triggers an 
endoplasmic reticulum (ER) stress response that results in the production of asparagine. 
The released asparagine is sensed by an alternative TCS that activates sil to modulate 
transcription of bacteriocin production. The resulting population-wide production of 
bacteriocins mediates killing of bacterial competitors and allows S. pyogenes to establish 
niche dominance in the host (137, 138).  
 
1.8 Rationale and Hypothesis  
Coordination of metabolism and virulence factor expression has proven to be critical for 
immune evasion and the establishment of infection by S. pyogenes. However, despite 
continuous efforts to understand the dominant asymptomatic state, little is known about the 
molecular processes employed by S. pyogenes to outcompete the endogenous microbiota 
and stably colonize the nasopharynx.  
 
In polymicrobial environments, intra- and interspecies competition is often driven by the 
production of short antimicrobial peptides called bacteriocins; this provides a mechanism 
by which S. pyogenes may compete for ecological stability in its host (86, 138). Using a 
recombinase-based in vivo expression technology system developed in our laboratory by 
Dr. Brent Armstrong, we previously demonstrated that spb bacteriocin expression is 
upregulated upon introduction of GAS in the mouse nasopharynx (100). Therefore, we 
hypothesize that the Spb bacteriocin systems contribute to the establishment of 
nasopharyngeal infection. To explore this hypothesis, we sought to 1) identify the 
regulatory cues and mechanisms utilized by S. pyogenes to induce bacteriocin production; 
2) characterize the inhibitory spectra of the Spb bacteriocins; and 3) assess the potential 
competitive advantage of the bacteriocins during nasopharyngeal infection. The work 
presented here will characterize the novel Spb two-peptide bacteriocins systems and 
provide greater insights into the mechanisms utilized by S. pyogenes to establish dominance 




























2.1 Bacterial strains, media, and growth conditions  
A complete list of bacterial strains used in this study can be found in Table 1. Molecular 
cloning experiments utilized the Escherichia coli XL1-Blue strain cultured at 37 °C in 
Luria-Bertani (LB) broth (Thermo Fisher Scientific, Waltham, MA, USA) with agitation, 
or Brain Heart Infusion (BHI; BD Biosciences, Franklin Lakes, NJ, USA) media containing 
1.5% (w/v) agar (Thermo Fisher Scientific). Media was supplemented with 150 μg mL-1 
erythromycin (Sigma-Aldrich Canada, Oakville, ON, Canada) as necessary. Streptococcal 
strains were grown in Todd-Hewitt broth (BD Biosciences) supplemented with 1% (w/v) 
Bacto Yeast Extract (BD Biosciences) (THY) and incubated at 37 °C under static 
conditions. When appropriate, 1.5% agar and/or 1 μg mL-1 erythromycin were added to the 
media. For bioactivity experiments utilizing galactose and glucose supplementation, filter 
sterilized 10% (w/v) stock solution of sugar (Sigma-Aldrich) was added at a final 
concentration of 0.5% to M17 (Oxoid, Hampshire, UK) broth (GalM17). For solid media 
preparation, M17 broth was supplemented with 1.5% agar and 0.1% (w/v) calcium 
carbonate (CaCO3). Indicator strains M. luteus and L. lactis spp. were grown in THY at 37 
°C under aerobic and static conditions, respectively. THY agar tubes were prepared with 
0.75% (w/v) agar. 
 
2.2 DNA manipulations 
2.2.1 S. pyogenes genomic DNA extraction 
For total genomic DNA extractions from S. pyogenes, 1.5 mL of overnight culture was 
centrifuged at 15,000 ´ g for 1 minute and washed with 0.2 mM sodium acetate. Cells were 
centrifuged again and resuspended in 500 μL lysis buffer (50 mM EDTA, 0.2% SDS) with 
0.02 μg RNase. Following an hour-long incubation at 70 °C, 50 μL of 5 M potassium 
acetate was added to precipitate proteins in a 1-hour incubation at –20 °C. Cells were then 
pelleted at 15,000 ´ g for 10 minutes. For DNA precipitation, the supernatant was 
transferred to a new tube with 1 mL ice-cold 95% ethanol and incubated at –20 °C for 1 
hour. Centrifugation was repeated, and the pellet was washed once in 1 mL ice-cold 70% 
ethanol. The resulting DNA was air-dried, resuspended in 100 μL Qiagen Elution Buffer 




















Strain/Strain No. Description Source 
Escherichia coli 
XL1-Blue Cloning Strain:  
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac 
[F′proABlaclqZΔM15 Tn10 (Tetr)]  
Stratagene 
Streptococcus pyogenes 
MGAS8232 M18 serotype isolated from a patient with acute 
rheumatic fever (GenBank accession: NC_003485.1) 
(139) 
MGAS8232 DspbJK spbJKL deletion mutant derived from MGAS8232  McCormick Lab 
MGAS8232 DspbMN spbMNI deletion mutant derived from MGAS8232 McCormick Lab 
MGAS8232 DspbJKMN MGAS8232 containing in-frame deletions of spbJKL 
and spbMNI operons 
McCormick Lab 
Indicator strains for bacteriocin typing 
1  Micrococcus luteus  Burton Lab 
2 Streptococcus pyogenes M52 Burton Lab 
3 Streptococcus constallatus Burton Lab 
4 Streptococcus uberis Burton Lab 
5 Streptococcus pyogenes M4 Burton Lab 
6 Lactococcus lactis spp. Burton Lab 
7 Streptococcus pyogenes M28 Burton Lab 
8 Streptococcus pyogenes M87 Burton Lab 
9 Streptococcus dysgalactiae Burton Lab 
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2.2.2 Polymerase chain reaction 
All polymerase chain reaction (PCR) primers were designed using Primer3Plus 
(http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi) or New England 
Biolabs Tm Calculator (https://tmcalculator.neb.com/#!/main) (Table 2) and supplied by 
Sigma-Aldrich. Reactions utilized Phusion High-Fidelity DNA polymerase (0.7 µL /100 
µL reaction) and 1 ´ High-Fidelity buffer (Thermo Fisher Scientific), 2 mM magnesium 
chloride (MgCl2; Thermo Fisher Scientific), and a 3 mM deoxyribonucleotide triphosphate 
(dNTP) mixture (Roche, Basel, Switzerland). Forward and reverse primers were added at 
a final concentration of 1 µM, and 1 µL template DNA was added per 100 µL total reaction 
volume. All reactions were performed in the MJ Mini or MJ Research PTC-200 Thermal 
Cyclers (Bio-Rad Laboratories, Hercules, CA, USA) using the following gene 
amplification conditions: 98 °C for 5 minutes to preheat the thermocycler; 98 °C for 30 
seconds for initial denaturation; 30 seconds at the calculated melting temperature (Tm) to 
anneal primers; 36 cycles of gene amplification at 72 °C (extension time: 30 seconds per 1 
kb); and a final 7-minute extension step at 72 °C. The thermocycler was held at 4 °C to 
indicate completed PCR reactions. 
 
2.2.3 DNA visualization 
DNA was visualized on 1% (w/v) agarose (Thermo Fisher Scientific) in 1 ´ TAE (40 mM 
Tris-acetate, 1 mM EDTA) buffer. DNA samples were mixed with loading dye buffer (40% 
[v/v] glycerol, 0.25% [w/v] bromophenol blue [International Biotechnologies, New Haven, 
CT, USA]) in a 5:1 ratio and loaded into pre-cast wells in the gel, along with a standard 1 
kb DNA molecular ladder (Invitrogen, Carlsbad, CA, USA). The PowerPac 200 
Electrophoresis Power Supply and Chamber (Bio-Rad) was used to run the gel at 100 V for 
1 hour. Agarose gels were stained with 0.05% (v/v) ethidium bromide in TAE for 15 
minutes and visualized under ultraviolet light (Gel Doc; Bio-Rad Laboratories).  
 
2.2.4 Plasmid isolation from E. coli 
Plasmid DNA was isolated from an overnight culture of E. coli using the QIAprep Spin 
Miniprep Kit (Qiagen) following the manufacturer’s instructions. All plasmids used in this 
study can be found in Table 3.  
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Table 2. Primers used in this study. 
Plasmid Primer Sequence (5¢® 3¢)a 
Primers for generating deletion constructs 
spbJK up XhoI for GCG CTCGAG AAACTCATTAAGCCATTCTTT 
spbJK up BamHI rev GCG GGATCC TGTATTCATAACGAATATCTCCT 
spbJK down BamHI for GCG GGATCC TGGTTTATAAATTAGGACATATTTAAG 
spbJK down XbaI rev GCG TCTAGA TCAAATTGAGCATGACGAAG 
spbMN up PstI for GCG CTGCAG TCATCTTAGTGACTTTTACTGTCGG  
spbMN up SalI rev GCG GTCGAC AAGAACAGTATCCTGGTTTCAAAA  
spbMN down SalI for GCG GTCGAC CCTCACTAAATATATAAATGACTATCTATCACTG 
spbMN down BamHI rev GCG GGATCC TAGAATCACTGCAGAAATAATAACAATACC  
covR up KpnI for CGC GGTACC AGTTGGTTGAAGACAATCTGGTATT 
covR up SalI rev CGC GTCGAC TTTCTTTGTCATTTATACCAACCCTT 
covR down SalI for CGC GTCGAC ATTCGTGAGAAATAAGTCATAT 
covR down BamHI rev CGC GGATCC GATACTGATCTTCGATATGG 
mga up PstI for CGC CTGCAG AGCTAATGTTGGTGTAAATTGACTGA 
mga up SalI rev  CGC GTCGAC ACTTACATGCATTAACTTCATGTCCT 
mga down SalI for CGC GTCGAC GCAACATCATCATAGGATTTCAGA 
mga down BamHI rev  CGC GGATCC ACTCCGTTGTTCTAACTGAT 
ccpA up KpnI for CGC GGTACC GTTTCCTTGTGTTTGTGGTGAAC 
ccpA up SalI rev CGC GTCGAC TCCTTTCTATTTGAAAATGACGCTTTC 
ccpA down SalI for CGC GTCGAC ACTAAGTAACTGTGACTTATGAGCAC 
ccpA down PstI rev CGC CTGCAG GTAGCGACGAAAAGCTGC 
sil up BamHI for CGC GGATCC GTAGTTTTTTTGAAAAAAACATTTC 
sil up SalI rev CGC GTCGAC GACAAAAATATTCATTTTAACCTTTA 
sil down KpnI for CGC GGTACC CGTTTCCTCCACTTATACTA 
sil down SalI rev CGC GTCGAC ATAGGATATCATTTGTAAAAGAC 
silDE up KpnI for CGC GGTACC CGTTTCCTCCACTTATACTA 
silDE up SalI rev CGC GTCGAC ATAGGATATCATTTGTAAAAGAC 
silDE down SalI for CGC GTCGAC AGTTTTAATTAAATATAATAAAATTC 
silDE down BamHI rev CGC GGATCC TGGTAAACAGATATTAATTGTT 
rgg up KpnI for CGC GGTACC CATGATACGTTGGCTTTGTCTA 
rgg up SalI rev CGC GTCGAC TTCTTTTTCCATTTTTCCCACTTT 
rgg down SalI for CGC GTCGAC GCAGATTTATGAGTTGCTTTCTATC 
rgg down BamHI rev CGC GGATCC CTTGGTAAACCAAGGTCGAA 
Primers for generating the complement plasmids 
PgyrA XmaI for GCG CCCGGG GCACCATCACCGACCAAGATTA 
PgyrA KpnI rev GCG GGTACC CATTTAAGGAATGCTCCTTTTCTAGTCAA 
spbMNI comp KpnI for GCG GGTACC ATGGAGATAAAGAAACTGGAAACATTTC 
spbMNI comp BamHI rev 
terminator SalI 
GCG GGATCC AAAAAAAGCACCGACTCGGTGCCACTTTTTCAA 
GTTGATAA GTCGAC TTAGTGAGGCCAGATAATATTTGTAGC 
Primers for sequencing and screening 
M13 for GTAAAACGACGGCCAG 
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M13 rev GTCATAGCTGTTTCCTG 
spbJKL integration for CTCATCATCTGTTGTAGGATATAGG 
spbJKL integration rev GTTTGGCTTCAAGAAGACC 
spbMNI integration for GAGATCGCTGTTTAAAAATAAGAGG 
spbMNI integration rev CTTGATACCATGTGAGCACTTCT 
Primers for qRT-PCR analysis 
gyrA RT for GGTTCGTATGGCTCAGTGGT 
gyrA RT rev TTCTCTTTCGCTTCCATCGT 
speC RT for TTTGAGCAGGCGTAATTCCT 
speC RT rev TTCAACGACACACACATTAAAC 
spbJ RT for GAAATTATGGATGAGGCC 
spbJ RT rev TTACCACCAACAAGTCG 
spbK RT for GGAACAATTTGAAGTGATG 
spbK RT rev CCATTACACGCATTAGGT 
spbM RT for GGAGATAAAGAAACTGGAAA 
spbM RT rev CCCAAAGAGTAATAGCTGTT 
spbN RT for GACAACAATGAAGGAATTAAC 












Table 3. Plasmids used in this study. 









Plasmid Descriptiona Source 
pG+host5 Temperature-sensitive Gram-positive/E. coli shuttle 
vector; Ermr 
(140) 
pG+host5::DspbJK spbJK deletion plasmid inserted into the genome of 
MGAS8232 
McCormick Lab 
pG+host5::DspbMN spbMN deletion plasmid inserted into the genome of 
MGAS8232 
McCormick Lab 
pG+host5::DspbJKMN Plasmid used to delete spbJK and spbMN operons in 
MGAS8232 
McCormick Lab 
pG+host5::DcovR Plasmid used to delete covR gene in MGAS8232 This study 
pG+host5::Dmga Plasmid used to delete mga gene in MGAS8232 This study 
pG+host5::DccpA Plasmid used to delete ccpA gene in MGAS8232 This study 
pG+host5::Dsil Plasmid used to delete the sil operon in MGAS8232 This study 
pG+host5::DsilDE Plasmid used to delete the silD and silE genes 
encoding an ABC-transporter in MGAS8232 
This study 
pG+host5::Drgg Plasmid used to delete rgg gene in MGAS8232 This study 
pTRKL2 Low-copy Gram-positive/E. coli shuttle vector; Ermr (141) 
pTRKL2::PgyrA pTRKL2 plasmid carrying the constitutive gyrA 
promoter 
McCormick Lab 
pTRKL2::PgyrA::spbMNI pTRKL2 containing spbMNI driven by the gyrA 




2.2.5 Preparation of E. coli competent cells 
For preparation of rubidium chloride competent cells, an overnight culture of E. coli XL1-
Blue was subcultured 1:100 in PSI broth (0.5% [w/v] Bacto Yeast Extract [BD 
Biosciences], 2% [w/v] Bacto Tryptone [BD Biosciences], 0.5% [w/v] magnesium 
sulphate, pH 7.6) and grown aerobically at 37 °C to an optical density at 600 nm (OD600) 
of 0.5. The bacteria were incubated on ice for 15 minutes followed by 5 minutes of 
centrifugation (5,000 ´ g) at 4 °C. The pellet was resuspended in 0.4 ´ the original volume 
of TfbI buffer (100 mM rubidium chloride, 50 mM manganese chloride, 30 mM potassium 
acetate, 10 mM calcium chloride, 15% [v/v] glycerol, pH 5.8) and chilled on ice for another 
15 minutes. Cells were centrifuged and resuspended in 0.04 ´ the original volume of TfbII 
buffer (75 mM calcium chloride, 10 mM rubidium chloride, 10 mM 3-(N-morpholino) 
propanesulfonic acid, 15% [v/v] glycerol, pH 6.5) and stored in 200 µL aliquots at -80 °C.  
 
2.2.6 E. coli transformation  
Recombinant plasmids were transformed into competent E. coli by heat-shock. Briefly, 
competent cells were thawed, 10 µL of the ligation reaction was added, and cells were 
incubated on ice for 30 minutes. Cells were shocked at 42 °C for 45 seconds and placed on 
ice for an additional 2 minutes. Cells were transferred to a new tube with 900 µL LB and 
incubated at 37 °C with aeration for 1 hour. The bacteria were plated on BHI agar with 
appropriate antibiotics and incubated overnight at 37 °C. Clones were verified via 
sequencing by the Sequencing Facility at the John P. Robarts Research Institute at Western 
University, London, ON, Canada.  
 
2.2.7 Preparation of S. pyogenes competent cells 
An overnight culture of S. pyogenes was used to inoculate THY broth supplemented with 
0.6% glycine (1:50). Hyaluronidase (1 mg mL-1) was added within two hours of incubation 
and bacteria were grown to an OD600 of ~0.3. Cells were pelleted at 7,000 ´  g for 5 minutes, 
washed once in 0.4 ´  the original volume with ice-cold 15% [v/v] glycerol, and resuspended 
again in 0.04 ´ 15% [v/v] glycerol. Competent cells were stored in 200 µL aliquots at -80 
°C until use.  
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2.2.8 S. pyogenes electroporation 
Correct plasmids were introduced into S. pyogenes by electroporation. Briefly, 2 μg of 
DNA were thoroughly mixed with electrocompetent cells thawed to room temperature. 
Cells were transferred to a 2 mm electroporation cuvette and pulsed exponentially at 2500 
V and 600 W using the Bio-Rad GenePulser. Bacteria were then transferred to 10 mL THY 
and recovered at 37 °C. After 3 hours, cells were pelleted at 6,000 ´ g and resuspended in 
1 mL THY. Cells were plated on THY and incubated at 37 °C until colonies were visible. 
When appropriate, erythromycin was added to solid media.  
 
2.2.9 Construction of deletion mutants  
References to genomic loci are based on the genome of S. pyogenes MGAS8232, an M18 
clinical isolate associated with acute rheumatic fever (139). In-frame deletion mutants in 
the genes encoding SpbJKL, SpbMNI, CovR, CcpA, Mga, Rgg, SilDE, and Sil were 
generated in the Gram-positive/E. coli shuttle vector, pG+host5 (140) (Table 3). Using the 
appropriate PCR primers (refer to Table 2), two ~500 bp fragments flanking the upstream 
and downstream regions of the gene of interest were amplified from MGAS8232. PCR 
products, as well as pG+host5, were digested using restriction endonucleases (New England 
Biolabs, Ipswich, MA, USA) and purified using the QIAquick PCR Purification Kit 
(Qiagen). Purified products were ligated together using T4 DNA Ligase (New England 
Biolabs). Ligations were performed with an insert:vector molar ratio of 5:1 and incubated 
overnight at room temperature. The resulting constructs were transformed into competent 
E. coli XL1-Blue and verified by DNA sequencing.  
 
Using the pG+host5 system which contains a temperature-sensitive origin of DNA 
replication and an erythromycin selection marker, target wild-type genes were replaced 
with a mutant allele via homologous recombination (Figure 4). This process has been 
previously described in detail (140). Briefly, knockout constructs were electroporated into 
S. pyogenes MGAS8232 and grown at 30 °C on THY agar supplemented with 
erythromycin. Visible colonies were cultured in THY broth with erythromycin at 30 °C for 
up to four days. Bacteria was streak plated onto THY with erythromycin and incubated at 














Figure 4. Molecular cloning strategy for generating gene deletions in the S. pyogenes 
MGAS8232 genome.  
In-frame genetic deletions were generated in S. pyogenes MGAS8232 using the pG+host5 
plasmid, which contains a temperature-sensitive origin of DNA replication and an 
erythromycin resistance marker. Briefly, bacteria were grown in THY supplemented with 
erythromycin at 30 °C to enable plasmid replication. At the non-permissive temperature 
(40 °C), plasmid-integrated colonies (i.e., single-crossover clones that have undergone the 
first recombination event) were screened. Selected clones were next cultured in THY 
without erythromycin at 30 °C to stimulate the double cross-over event that leads to plasmid 































the plasmid remain resistant to erythromycin. To verify the first integration event into the 
chromosome, genomic DNA was extracted from individual colonies grown at 40 °C and 
plasmid integration was confirmed by PCR. Correct clones were then subcultured 1:100 in 
THY broth without antibiotics at 30 °C. Bacteria were streaked daily on THY to isolate 
individual colonies. Patching of individual colonies on THY with and without 
erythromycin was used to identify clones that lost resistance to erythromycin, indicating 
that the plasmid was cured. Sensitive clones were next verified by PCR and DNA 
sequencing. 
 
2.2.10 Complementation of spb mutants  
For complementation of the spb in-frame deletions, DNA fragments containing the spbMNI 
genes were amplified from MGAS8232 without its native promoter element and inserted 
under control of the gyrA promoter in pTRKL2 as previously described (141). The resulting 
plasmid was introduced into MGAS8232 DspbJKMN for constitutive expression of the 
spbMN operon.  
 
2.3 Bioactivity assays 
Bacteriocin-typing or “P-typing” is a method used to characterize bacteria based on their 
production of bacteriocins or sensitivity to a range of different bacteriocins. Patterns of 
inhibitory activity are determined using two fundamental assays commonly referred to as 
the simultaneous- and deferred-antagonism tests. These assays, which are often performed 
on solid media, are used to identify indicator organisms that are sensitive to bacteriocin 
production (142). In particular, typing of streptococci utilizes a set of nine indicators (I1-I9) 
(143), which are listed in Table 1.  
 
The simultaneous antagonism assay produces an environment where test strains (i.e., 
bacteriocin-producing strains) and selected indicators are in direct competition (142). 
Briefly, overnight cultures of MGAS8232 wild-type, DspbJK, DspbMN and DspbJKMN 
were spotted (10 µL) on 0.5% GalM17 agar buffered with 0.1% CaCO3 and incubated 
overnight at 37 °C under atmospheric and elevated (5%) levels of CO2. A THY agar tube 
inoculated 1:100 with an overnight culture of the target indicator strain was poured on the 
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pre-inoculated plate and incubated for 24–48 hours at 37 °C to form a confluent bacterial 
lawn. However, bacteriocins are also diffusible inhibitors that are released during the initial 
stages of bacterial growth (142). Therefore, to investigate diffusion of inhibitory substances 
into the media, the deferred antagonism assay was utilized. Test strains were streaked from 
one end of the plate to the other using a sterile cotton swab and incubated under similar 
conditions above. Following overnight incubation, bacterial growth was mechanically 
removed, and all remaining viable cells were exposed to chloroform. An overnight culture 
of the target indicator was streaked perpendicular to the test strain, and bacteria were 
incubated at 37 °C for 24 hours.  
 
2.4 Growth curves 
S. pyogenes MGAS8232 wild-type and isogenic mutant strains were grown from frozen 
stocks and subcultured twice (1:100 dilution) in THY broth at 37 °C. On day 3, 6 mL 
overnight culture was used to inoculate 100 mL pre-warmed THY to early log-exponential 
phase. Bacterial samples were adjusted to an OD600 of 0.02, and loaded in triplicate, along 
with blank controls, in a sterile 96-well plate. Bacteria were grown under appropriate 
conditions and OD600 measurements were recorded every 15 minutes for 18 hours using the 
Synergy HTX Multi-Mode Microplate Reader (BioTek, Winooski, VT, USA). 
 
2.5 In vivo experiments 
2.5.1 Ethics Statement  
All animal experiments were conducted in accordance with the Canadian Council on 
Animal Care Guide to the Care and Use of Experimental Animals. The animal protocol 
(2017-024) was approved by the Animal Use Subcommittee at Western University 
(London, ON, Canada) (Appendix 1). 
 
2.5.2 Murine nasopharyngeal infection model 
Mice were bred and housed in the West Valley Barrier Facility at Western University. All 
experiments were performed using transgenic C57BL/6 (B6) mice expressing the major 
histocompatibility complex (MHC) II human leukocyte antigen (HLA)-DQ8 donated from 
the Kotb Laboratory (144, 145). As previously described (82, 83, 146), HLA-DQ8 mice 9–
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13 weeks of age were intranasally inoculated with ~108 CFU of S. pyogenes grown to early 
exponential phase (OD600 ~0.2–0.4) and resuspended in Hanks’ Balanced Saline Solution 
(HBSS; Life Technologies, Carlsbad, CA, USA). Mice were anaesthetized with Forane 
(isoflurane, USP; Baxter International, Deerfield, IL, USA) and nasally infected with a 7.5 
µL dose of bacteria per nostril. At 48 hours post-infection, mice were sacrificed and their 
complete nasal turbinates (cNTs), including the nasal-associated lymphoid tissue (NALT), 
nasal turbines (NT), and maxillary sinuses (MS), were extracted (Figure 5). The cNTs were 
homogenized in TE (10 mM Tris-HCl, pH 8.0; 1 mM EDTA) buffer, serially diluted, and 
plated on Trypticase Soy Agar (TSA) supplemented with 5% sheep’s blood (BD 
Biosciences) for bacterial enumeration. Counts less than 25 CFU per 100 µL of cNT were 
considered below the theoretical limit of detection (147). 
 
2.5.3 Time-course of S. pyogenes infection 
Mice were inoculated intranasally with 15 µL HBSS-vehicle or wild-type S. pyogenes 
MGAS8232 on day 0 as previously described (see above). To examine whether the length 
of infection affected microbial abundance in the nasopharynx, mice were anesthetized and 
sacrificed at 24-hour time points for up to 96 hours post-infection. Mice infected with the 
vehicle control were sacrificed of day 0. All cNTs were processed on TSA, BHI, and TSA 
with 5% sheep’s blood for bacterial enumeration, and stabilized in RNAprotect Cell 
Reagent (Qiagen) for storage at -80 °C. 
 
2.1.1 Nasopharyngeal competition experiments 
To determine whether Spb production outcompetes spb-deficient strains of streptococci, S. 
pyogenes MGAS8232 and the DspbJK, DspbMN, and DspbJKMN mutants were grown to 
early exponential phase and prepared individually for intranasal inoculation. An equal 
volume of wild-type MGAS8232 was mixed with each of the isogenic mutants for a 
colonization ratio of 1:1. These strains were then diluted 1:2 with HBSS to the appropriate 
inoculum dose. Control mice were infected with either 108 CFU MGAS8232 wild-type or 
the respective mutant strain. Mice were euthanized 48 hours post-inoculation and cNTs 
















Figure 5. Isolation of murine complete nasal turbinates. 
(A) A cross-section view of a mouse head to visualize the nasal passage. (B) Front view of 
the nasal passage, including the maxillary sinuses (MS), nasal turbines (NT) and the nasal-
associated lymphoid tissue (NALT) [Image modified (148)]. The collective tissue 


















































for bacterial enumeration on TSA with 5% sheep’s blood. In some experiments, mice were 
administered 2 mg L-1 neomycin sulphate in their drinking water two days prior and 
throughout the length of infection to reduce variability in the nasal microbiota. Other 
experiments utilized clean water to examine the effects of background nasal microbiota on 
colonization efficiency. cNTs collected from non-antibiotic treated mice were stabilized in 
RNAprotect Cell Reagent and stored at -80 °C for future analysis. 
 
2.1.2 Complementation of spbMNI  
The expression plasmid pTRKL2, containing spbMNI under control of the gyrA promoter 
(pTRKL2::PgyrA::spbMNI), was transferred to MGAS8232 DspbJKMN by 
electroporation. To determine whether plasmid-based complementation of one functional 
bacteriocin system was able to restore antimicrobial activity, mice were inoculated with 
~108 CFU of S. pyogenes grown to early exponential phase. Nasal inoculations were 
performed as described above.  
 
2.1.3 Co-colonization ratio 
Hemolytic colonies recovered from control-treated mice and mice inoculated with 
competing bacterial strains were patched on GalM17 agar supplemented with 0.1% CaCO3 
and incubated overnight at 37 °C in 5% CO2. Colonies with inhibitory activity, or lack 
thereof, against M. luteus were quantified by clearance zones or overgrowth, respectively. 
 
2.2 S. pyogenes RNA extraction  
S. pyogenes cells, from frozen or fresh overnight cultures (OD600 ~0.2–0.8), were incubated 
with 1 mL RNAprotect Cell Reagent for 5 minutes at room temperature. The cells were 
centrifuged for 10 minutes at 15,000 ´ g and resuspended in 500 µL Tris-EDTA Glucose 
(10 mM Tris, 2 mM EDTA, 25% glucose) buffer with 5 µL of 20 mg mL-1 lysozyme and 
5 µL of 10 U µL-1 mutanolysin. Cells were incubated in 37 °C water bath for 1 hour. 
Following centrifugation at 21,000 ´ g, cells were resuspended in 500 µL lysis buffer (50 
mM EDTA, 0.2% SDS) with 10 µL 10 mg mL-1 proteinase K and incubated at 65 °C for 2 




2.3 Quantitative reverse transcriptase PCR 
RNA was used to generate cDNA using SuperScript II Reverse Transcriptase (RT) and 
Random Primers purchased from Invitrogen Life Technologies. Sequence-specific primers 
were designed for spb antimicrobial genes with an amplicon length of ~200 bp. All gene 
samples, including the gyrA housekeeping gene and speC positive control, were first 
amplified from wild-type MGAS8232 genomic DNA and quantified using the NanoDrop 
One/OneC Microvolume UV-Vis Spectrophotometer (Thermo Fisher Scientific). Purified 
products were adjusted to a starting concentration of 5 ng µL-1 (100) and serially diluted to 
10-8 in Qiagen Elution Buffer. The quantitative reverse transcriptase (qRT)-PCR reactions 
were performed using iQ SYBR Green Supermix (Bio-Rad) according to manufacturer’s 
recommendations. All reactions were performed using the appropriate primers (refer to 
Table 2) and template, with an additional no template and minus RT control. Samples were 
run on a Corbett Life Sciences Rotor-Gene 6000 (Sydney, Australia) using the following 
gene amplification conditions: 95 °C for 5 minutes, denaturation for 10 seconds at 95 °C, 








































3.1 Confirmation of spb deletion mutants 
In-frame deletions of the spbJK and spbMN operons in S. pyogenes MGAS8232 were 
previously designed and generated by Dr. Armstrong of the McCormick laboratory (Table 
3; Figure 6A). Deletion mutants were validated using PCR amplification with primers in 
the flanking regions of the deleted regions. This analysis demonstrated that compared to 
wild-type, the MGAS8232 DspbJK strain was found to have a 1854 bp deletion in the spbJK 
region, the DspbMN strain featured a 1049 bp deletion, and the double mutant was shown 
to include both these deletions (Figure 6B). Growth in THY media was compared to ensure 
that the mutations had no detrimental effects on the growth rate of S. pyogenes. MGAS8232 
DspbJK, DspbMN, and DspbJKMN mutants were found to have no major growth difference 
when compared to wild-type (Figure 6C). 
 
3.2 In vitro expression of spb genes is induced by CO2 and 
galactose 
Virulence factor gene expression in S. pyogenes is coregulated by multiple regulatory loci 
in a growth phase-dependent manner (110, 131). With regard to bacteriocins produced by 
other Gram-positive bacteria, patterns of gene expression have been linked directly to the 
growth cycle and changes in environmental conditions (149, 150). For example, it has been 
shown that environmental cues such as pH (150, 151), temperature (152, 153), and the 
accumulation of specific quorum-sensing molecules (149) are able stimulate bacteriocin 
synthesis. To determine the optimal conditions required to induce Spb production by S. 
pyogenes, wild-type and isogenic mutant strains of MGAS8232 were grown on M17 media 
supplemented with various carbohydrate sources and cultivated under different growth 
parameters; antimicrobial activity was detected by growth inhibition of indicator strains. 
Here, we show that growth in the presence of 5% CO2 and 0.5% galactose are distinct 
regulatory cues that appear to activate spb expression in vitro. Under these conditions, S. 
pyogenes strains encoding both or one of the spb gene clusters produced an antimicrobial 
compound that was active against M. luteus. To confirm that the spb operons were 
responsible for the antimicrobial activity of MGAS8232, the double-bacteriocin knockout 
strain was also screened for activity. As anticipated, the DspbJKMN mutant showed no 















Figure 6. Verification and evaluation of spb deletion mutants in S. pyogenes 
MGAS8232. 
(A) To confirm in-frame deletions of the spbJK and spbMN operons in MGAS8232, 
primers outside of the homologous recombination site were used to amplify genomic DNA 
extracted from wild-type and isogenic mutants. (B) PCR products were visualized on a 1% 
agarose gel stained with ethidium bromide. (C) Growth of S. pyogenes MGAS8232 and 
DspbJK, DspbMN, and DspbJKMN mutants in THY at 37 °C was measured by OD600 over 











































in the absence of CO2, suggesting that Spb activity is CO2-dependent (Figure 7A, B).  
 
Next, we sought to examine the effect of incubation time on bacteriocin production. To 
determine the optimal incubation period, S. pyogenes strains were grown at 12-hour 
intervals for up to 48 hours before simultaneous antagonism testing against M. luteus. No 
differences in antimicrobial activity between incubation periods were observed, as zones 
of clearance surrounding spb-producing strains were comparable to those produced after 
24 hours as illustrated in Figure 7A. Lastly, to investigate the effect of different carbon 
sources on Spb production, test strains were cultured on M17 agar supplemented with 0.5% 
glucose under atmospheric and elevated levels of CO2. Notably, all MGAS8232 strains, 
including the double bacteriocin-deficient strain, produced an inhibitory substance that was 
active against M. luteus under CO2 (Figure 7C). These findings suggest Spb bacteriocin 
production is induced in response to galactose and CO2, and that glucose and CO2 may 
activate other unidentified bacteriocin-like inhibitory substances by S. pyogenes. 
 
3.3 Inhibitory spectra of the Spb bacteriocins 
To identify the inhibitory spectra of the Spb bacteriocins, S. pyogenes MGAS8232 wild-
type and isogenic mutant strains were tested against a set of defined indictors listed in Table 
1. Test strains were spotted on M17 media supplemented with 0.5% galactose and cultured 
under atmospheric and elevated levels of CO2. Using the simultaneous assay, we 
demonstrate that S. pyogenes strains encoding either one or both of the spb loci exhibit 
antimicrobial activity against all M-types of S. pyogenes, S. dysgalactiae, and M. luteus 
when grown with 5% CO2 (Table 4). In the absence of CO2, visible zones of clearance were 
not observed. These results suggest that the Spb bacteriocins produced by S. pyogenes 
possess a narrow range of killing that is limited to closely related bacterial species.  
 
3.4 Time-course analysis 
To examine whether microbial abundance is affected by bacteriocin production over time, 
an experiment using the murine model of S. pyogenes acute nasal infection was designed 
to analyze the time course of infection in the presence of the microbiota. Previous time-
course experiments utilizing this model have been performed with neomycin-treated 













Figure 7. Spb production by S. pyogenes MGAS8232 is induced by galactose and CO2. 
Bioactivity assays for detecting antimicrobial activity by S. pyogenes MGAS8232 wild-
type and isogenic mutant strains. (A) Cells from overnight cultures of wild-type and spb-
deficient strains DspbJK, DspbMN, and DspbJKMN were spotted on M17 media 
supplemented with 0.5% galactose and 0.1% CaCO3 and incubated overnight at 37 °C with 
atmospheric and elevated levels of CO2. A second agar layer inoculated with M. luteus was 
grown overtop, forming a confluent bacterial lawn. (B) All strains and plates were prepared 
as described in Panel A. Overnight cultures of S. pyogenes were streaked across agar plates. 
Cells were mechanically removed and treated with chloroform. M. luteus was streaked 
perpendicular to the test strains. (C) Cells from overnight cultures of wild-type and isogenic 
mutants were spotted on M17 media supplemented with 0.5% glucose and 0.1% CaCO3 
and incubated for 24 hours at 37 °C under atmospheric and elevated levels of CO2. 

































Table 4. Antimicrobial spectra of the Spb bacteriocins.  
Indicator  
Elevated CO2 (5%) 
MGAS8232 DspbJK DspbMN DspbJKMN 
M. luteus  + + + + 
S. pyogenes M52 + + + + 
S. constallatus - - - - 
S. uberis - - - - 
S. pyogenes M4 + + + + 
L. lactis spp. - - - - 
S. pyogenes M28 + + + + 
S. pyogenes M87 + + + + 
S. dysgalactiae + + + + 














However, in the current study, neomycin was not administered to examine potential 
interactions between S. pyogenes and the nasopharyngeal microbiota. HLA-DQ8 
transgenic mice were intranasally inoculated with S. pyogenes MGAS8232 and sacrificed 
at 24, 48, 72, and 96-hour time-points. Control mice received saline solution and were 
sacrificed on day 0 for microbiome analysis. Murine cNTs were removed, homogenized 
and the S. pyogenes burden in the nasopharynx was determined by growth of hemolytic 
colonies on TSA with 5% sheep’s blood agar. Consistent with previous findings from our 
laboratory (82), we show that mice sacrificed at the 48-hour endpoint had the highest load 
of S. pyogenes in the nasopharynx (Figure 8A). By 96 hours, CFU of S. pyogenes were 
dramatically reduced but not completely eliminated from the nasopharynx. However, 
clearance has been shown to take up to 6 days (82). Furthermore, through the administration 
of water lacking antibiotics, these data demonstrate that S. pyogenes is able to establish an 
acute infection. In addition to TSA with 5% sheep’s blood agar, the endogenous murine 
nasal microbiota was enumerated on various nutrient-rich mediums. The nasopharyngeal 
burden recovered on TSA and BHI agar were comparable to the total bacterial counts 
recovered on TSA with 5% sheep’s blood agar (Figure 8B), and therefore, not shown. Of 
note, counts of total bacteria and S. pyogenes in the nasopharynx were remarkably similar, 
indicating that non-streptococcal bacteria were only detected when CFU of S. pyogenes 
were low. These results indicate that another approach, such as 16S small subunit ribosomal 
RNA (rRNA) sequencing, may be required to identify changes in microbial diversity and 
abundance in the nasopharynx in response to bacteriocin production. 
 
3.5 Evaluation of Spb systems during nasopharyngeal 
infection 
Bacteriocins are considered one of the major driving forces of intraspecies bacterial 
competition within a biological niche (92, 101, 154). In humans, the composition of upper 
respiratory tract microbiome is particularly complex and frequently colonized by both 
commensal and pathogenic bacteria, including many species of streptococci (155, 156). 
Therefore, it is likely that organisms that exist within this environment produce bacteriocins 
to promote colonization. To test whether the Spb bacteriocin systems play a role in the 
establishment of nasopharyngeal infection by S. pyogenes, mice were infected with 















Figure 8. Time-course analysis of mice infected with S. pyogenes MGAS8232. 
HLA-DQ8 transgenic mice were intranasally inoculated with ~108 CFU of S. pyogenes 
MGAS8232 and sacrificed at 24, 48, 72, and 96 hours post-infection. Control mice received 
saline solution and were sacrificed on day 0 (n ³ 3 for each group). The nasopharyngeal 
burden of (A) S. pyogenes and (B) total bacteria were enumerated at each time point. Data 
points represent CFU recovered from an individual mouse. Horizontal bars represent the 








































collected at 48 hours post-infection and used to assess the bacterial burden. Mice infected 
with wild-type MGAS8232 or either of the single-bacteriocin deficient mutants were able 
to establish an acute infection in HLA-DQ8 mice more effectively than the double-
bacteriocin knockout mutant. Overall, a significant reduction in the bacterial burden 
recovered from the cNTs of DspbJKMN-treated mice was observed compared to the wild-
type and the single bacteriocin-producing strains, suggesting that infection of the 
nasopharynx by S. pyogenes requires at least one functional bacteriocin system (Figure 9A). 
 
In addition, to confirm that the wild-type and mutant strains retained their antimicrobial 
phenotypes, hemolytic colonies from the cNTs were cultured and spot plated onto 0.5% 
GalM17 agar buffered with 0.1% CaCO3 (Figure 9B). Notably, the colonies recovered from 
an in vivo environment recapitulate the in vitro phenotype of bacteriocin activity. Taken 
together, these results suggest an important role for Spb bacteriocin production in 
nasopharyngeal infection by S. pyogenes. 
 
3.6 In vivo competition analyses between MGAS8232 wild-
type and spb mutants 
From an ecological perspective, bacteriocin production is considered an important trait in 
the context of colonization and bacterial fitness (157). To explore whether wild-type S. 
pyogenes could interfere with nasal infection by mutant strains of spb, a competition model 
was employed in vivo. In this way, the application of the spb mutants allowed us to use 
these bacteria as a proxy for competing organisms during colonization and infection. In 
turn, this would give us an indication of whether the spb bacteriocin systems provide S. 
pyogenes with a competitive advantage over other streptococcal strains and species. Again, 
using the murine model of acute nasal infection, HLA-DQ8 transgenic mice were 
inoculated with mixtures of MGAS8232 wild-type and DspbJK, DspbMN, or DspbJKMN 
for a period of 48 hours. As shown in Figure 9A, when the S. pyogenes MGAS8232 wild-
type, DspbJK and DspbMN strains were instilled individually, they were able to establish 
infection unlike the bacteriocin-deficient strain DspbJKMN. Notably, co-inoculation 
appeared to impair all spb-producing strains from establishing infection (Figure 10A). 















Figure 9. One functional bacteriocin system is required for efficient nasopharyngeal 
infection by S. pyogenes. 
Transgenic mice were intranasally infected with ~108 CFU of S. pyogenes MGAS8232 
wild-type, DspbJK, DspbMN, or DspbJKMN for 48 hours (n ³ 10 per group). (A) The 
nasopharyngeal burden was assessed. Each data point represents CFU from the cNT of one 
mouse. Horizontal solid lines are the median of 10 independent experiments. The dotted 
horizontal line is used to indicate the theoretical limit of detection (25 CFU/100 µL). 
Statistical differences between groups were determined using the Mann-Whitney U test (* 
P < 0.05, ** P < 0.01). (B) CFU recovered from mice were tested for bacteriocin activity 









































Figure 10. Nasal coinfection with S. pyogenes MGAS8232 wild-type and spb mutants 
reduces the bacterial burden in the nasopharynx but appears to promote a wild-type 
dominant population. 
Transgenic mice were co-inoculated in a 1:1 ratio with MGAS8232 wild-type and either of 
the spb-deficient strains: DspbJK (n = 7), DspbMN (n = 6), or DspbJKMN (n = 21 without 
neomycin; n = 10 with neomycin) (108 total CFU). (A) The nasopharyngeal burden was 
assessed at 48 hours from 10 independent experiments. Data points represent CFU 
recovered from the cNT of individual mice. The horizontal bars and dotted line represent 
the median of each group and the theoretical limit of detection (25 CFU/100 µL), 
respectively. (B) Colonies from wild-type (n = 395), DspbJKMN (n = 394), and coinfected 
(n = 541) mice were patched on GalM17 agar supplemented with 0.1% CaCO3 and tested 
for bacteriocin activity against M. luteus. Bacterial recovery from mice with CFU counts 
below the limit of detection were omitted. (C) The ratio between MGAS8232 wild-type 
and DspbJKMN was determined using the simultaneous antagonism assay. Clearance and 
overgrowth phenotypes were quantified and used to distinguish strains. Bars represent the 
mean ± SD. Significant differences were determined by the Chi-squared test (*** P < 



































significantly less CFU of S. pyogenes were retrieved from the mice, suggesting that 
competitive interactions between the two strains were able to block infection. To evaluate 
whether the presence of the spb bacteriocin systems provided a competitive advantage 
during nasopharyngeal colonization, the simultaneous antagonism assay was used to 
quantify the ratio of wild-type to DspbJKMN bacteria that colonized coinfected mice 
(Figure 10B). Phenotypic analysis of the bacteria recovered from the coinfected mice 
revealed a significantly higher rate of recovery for wild-type versus the DspbJKMN mutant 
(Figure 10C). This striking difference in recovery indicates that the spbJKMN systems 
gives S. pyogenes a competitive advantage against streptococcal species that may not 
encode these systems.  
 
3.7 Plasmid-based complementation of SpbMN 
To further confirm that Spb is involved in establishing infection, we genetically 
complemented the MGAS8232 DspbJKMN isogenic mutant using the Gram-positive/E. 
coli shuttle vector pTRKL2 to generate strain MGAS8232 DspbJKMN containing 
pTRKL2::PgyrA::spbMNI (Table 3), and confirmed transformation by PCR amplification 
(Figure 11A). Despite successful transformation, the MGAS8232 DspbJKMN containing 
pTRKL2::PgyrA::spbMNI strain did not rescue the antimicrobial phenotype in vitro (data 
not shown). Although antimicrobial activity was not restored to the double-bacteriocin 
deficient strain in vitro, we utilized the complement strain in our acute infection model 
using HLA-DQ8 transgenic mice. Consistent with our in vitro data, MGAS8232 
DspbJKMN containing pTRKL2::PgyrA::spbMNI proved to be ineffective at restoring 
antimicrobial activity following murine nasopharyngeal passage. It is important to note that 
although there was no statistical difference between the bacterial burden in mice infected 
with the S. pyogenes MGAS8232 DspbJKMN and DspbJKMN containing 
pTRKL2::PgyrA::spbMNI strains, there was a trend towards higher CFU recovery in the 
DspbJKMN + pTRKL2::PgyrA::spbMNI-treated group compared to the non-complemented 
mutant (Figure 11B). It also appears as though many of the colonies recovered from murine 
cNTs were found to be sensitive to erythromycin, indicating that the plasmid may have 
been lost during infection (Figure 11C). Based on these findings, plasmid-based 












Figure 11. Plasmid-based complementation of SpbMN in S. pyogenes MGAS8232 
DspbJKMN does not increase the bacterial burden in the nasopharynx or restore 
antimicrobial activity.  
(A) Integration of the pTRKL2 plasmid containing spbMNI under control of the gyrA 
promoter into S. pyogenes MGAS8232 DspbJKMN. Genomic DNA was amplified via PCR 
and visualized on a 1% agarose gel. (B) Transgenic mice were intranasally infected with 
108 CFU of either S. pyogenes MGAS8232 DspbJKMN or MGAS8232 DspbJKMN 
containing pTRKL2::PgyrA::spbMNI. The nasopharyngeal burden was assessed from 
murine cNTs 48 hours post-infection. Data points represent CFU of individual mice. 
Horizontal bars represent the median. The horizontal dotted line indicates the theoretical 
limit of detection (25 CFU/100 µL). Significance determined by Mann-Whitney U test (ns, 
not significant). (C). Colonies recovered from murine cNTs were tested for bacteriocin 
activity against M. luteus using the simultaneous antagonism assay on GalM17 agar 




























high rate of excision throughout the length of infection, this approach could not reliably 
restore the wild-type phenotype. Together this suggests that an alternative method to 
plasmid complementation for spbJKMN should be explored to fully validate the role of 
these bacteriocins in establishing infection by S. pyogenes. 
 
3.8 In vitro and in vivo detection of spb expression 
Recent findings from our laboratory have demonstrated that transcription of spbM is highly 
upregulated at 48 hours following infection in the mouse nasopharynx. In comparison, 
spbM transcripts were hardly detectable in vitro. This suggests that bacteriocin-encoding 
genes are transcribed in an in vivo environment, where bacteriocin production may be 
advantageous for mediating competition against other bacteria (100). Because GAS 
infection of the nasopharynx is capable of inducing spbM expression, we examined whether 
infection would increase other spb transcripts similarly. Using qRT-PCR, speC, spbJ, spbK 
and spbM transcripts were analyzed from wild-type S. pyogenes MGAS8232 grown under 
in vitro (OD600 ~0.2 or ~0.8) and in vivo (following 48-hour infection) conditions. All data 
were normalized to internal housekeeping gene gyrA, and expression fold changes were 
determined using the 2-DDCt method (158). The speC gene was used as a positive control. In 
this study, we demonstrate that spbM transcription is 8-fold greater in vivo compared to 
wild-type MGAS8232 grown at early and late exponential phase. These findings support 
previous data reported from our laboratory (100). Similarly, expression of spbJ and spbK 
genes were upregulated under in vivo growth conditions. Notably, spbJ transcripts were 
significantly increased in the nasopharynx, with a 2000- and 500-fold difference in gene 
expression relative to early and late in vitro conditions, respectively (Figure 12). These 
findings provide strong evidence to suggest that the spb genes are specifically induced in 





















Figure 12. Transcription of bacteriocin-encoding genes are upregulated in vivo during 
nasopharyngeal infection. 
Expression analyses of spb bacteriocin-encoding genes. Total RNA was isolated from 
cultures of S. pyogenes MGAS8232 grown to OD600 ~0.2 or ~0.8 (early and late in vitro 
conditions, respectively; n = 4) and from HLA-DQ8 mice intranasally infected with 
MGAS8232 for 48 hours (n = 2; in vivo conditions). Transcription levels of speC (positive 
control), spbJ, spbK, and spbM were determined by SYBR green qRT-PCR and normalized 
to the housekeeping gene gyrA. Data are presented as fold change from wild-type in vivo 
relative to in vitro growth conditions. Data represent the mean of four independent 


























































































4.1 Discussion  
S. pyogenes is a globally prominent bacterial pathogen with the propensity to colonize the 
skin and upper respiratory tract of a human host (1, 23). Successful adaptation to different 
tissues is, in part, due to S. pyogenes’ ability to sense variations in the external environment 
and rapidly alter its gene expression profile. Due to S. pyogenes’ remarkable versatility, 
ongoing research efforts are focused on identifying the spatial and temporal patterns of 
regulation that control virulence factor gene expression and immune-evasion mechanisms 
utilized by S. pyogenes to establish infection (110, 131, 132, 137). In comparison, the 
processes governing ecological stability, bacterial fitness, and competition against the 
microbiota, which are vital for colonization, remain poorly understood. 
 
Microbial communities within humans are often characterized as competitive and complex 
environments that play an important role in determining health and disease. Resident 
microbiota are involved in many human biological processes, including modulation of the 
immune system, metabolism, epithelial development, as well as the prevention of 
colonization by opportunistic pathogens (159, 160). In any given biological niche, 
competition between microorganisms is driven by the need to acquire finite resources such 
as space and nutrients. In order to meet these demands, bacteria have adapted evolutionary 
traits and tools (i.e., degradative enzymes, bacteriocins and antimicrobial compounds, and 
mechanisms to disrupt quorum sensing-mediated signalling) to compete with one another 
(159, 161). 
 
Opportunistic pathogens such as streptococci must compete with a variety of pre-existing 
bacteria to colonize the upper respiratory tract of humans. In many cases, direct interactions 
between bacteria of the same or closely related species are mediated through the production 
of bacteriocins (101, 159, 162); a mechanism widely used by streptococci. For example, 
bacteriocins salivaricin (Sal) A and SalB produced by S. salivarius – a well-characterized 
colonizer of the oral cavity – are able to inhibit growth of pathogenic streptococci, including 
S. pyogenes (163, 164). However, bacteriocins are not exclusively produced by commensal 
bacteria. Invaders of the upper respiratory tract and the oral cavity, such as S. pneumoniae 
and Streptococcus mutants, also utilize bacteriocins to mediate intraspecies competition 
(92, 101, 161, 162). While these groups have all demonstrated an improved ability to 
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colonize when compared to their bacteriocin-deficient counterparts, S. pyogenes also 
encodes a number of bacteriocin genes that have received little recognition. In this study, 
we demonstrate that S. pyogenes utilizes two novel class IIb bacteriocin systems to establish 
infection and strain dominance within the polymicrobial environment of the mouse 
nasopharynx. 
 
Recently published findings from our laboratory have identified and characterized a novel 
two-component class IIb bacteriocin in S. pyogenes, which has been designated as the 
spbMN locus (100). Based on unpublished data, S. pyogenes appears to encode a second 
proximal type IIb system with potential genetic redundancy to spbMN. In turn, we 
designated these open reading frames as the spbJ and spbK genes. To characterize SpbJK 
and SpbMN in terms of their inhibitory spectrum, multiple approaches, including 
recombinant peptide expression and bioactivity testing, have been utilized. Using 
recombinant expression of SpbM and SpbN, a number of different streptococcal species, 
including S. pyogenes, S. dysgalactiae, S. uberis, as well as other Gram-positive bacteria 
such as M. luteus and L. lactis were shown to be susceptible to antimicrobial activity (100). 
To determine the range of SpbJ and SpbK activity, a similar approach was attempted; 
however, because SpbK appears to be toxic in E. coli, recombinant peptide expression 
proved to be less feasible. A goal of this project was thus to determine the regulatory cues 
required to induce expression of spb in vitro. This would allow us to test for antimicrobial 
activity using the standard simultaneous and deferred antagonism assays. Through 
empirical analysis, we show that spb-mediated inhibition is induced in response to 
galactose and CO2. To formally demonstrate that the spb operons are functionally active in 
S. pyogenes, the double-bacteriocin knockout strain was also screened for antimicrobial 
activity. Under the same conditions, we show that the DspbJKMN strain is unable to inhibit 
grown of the Spb-sensitive indicator M. luteus (Figure 7A, B). Since most bacteriocins have 
a narrow range of killing, it is widely thought that they play a role in mediating intraspecies 
competition (157, 162). To investigate this assumption, we tested the wild-type and 
isogenic mutant strains of MGAS8232 for bacteriocin production against a defined set of 
nine indicator strains listed in Table 1. Although there was significant variability between 
experiments, the putative inhibitory spectrums have been reported in Table 4. We speculate 
that SpbJK and SpbMN are active against several S. pyogenes serotypes, including M52, 
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M4, M28, M87 strains, M. luteus and S. dysgalactiae, and that the Spb systems possess a 
similar inhibitory range. Interestingly, both susceptibility testing methods have reported 
slightly different antimicrobial targets. We predict that the observed disparities are due to 
differences in protein expression levels. Based on these findings, further testing is required 
to determine the range of targets susceptible to SpbJK and SpbMN. Moreover, it would be 
of interest to identify the antimicrobial compound that is activated in response to glucose 
and CO2 (Figure 7C). 
 
It is possible that other regulatory signals may also induce expression of spb by S. pyogenes. 
It has been recently reported that in the M179 serotype S. pyogenes strain JS12, bacteriocin 
production is stimulated through a series of sequential events involving the sil locus. In this 
strain, which contains a fully intact sil, host cell membrane-triggered stress caused by the 
delivery of SLS and SLO is able to upregulate asparagine synthesis (137, 138). Asparagine 
appears to mediate activation of sil in a SilCR-dependent manner, which upregulates 
bacteriocin production (138). This proposed mechanism for Spb regulation and transport is 
possible in strains encoding an intact sil locus; however, it is currently unknown what 
replaces sil function in S. pyogenes strains with mutations in this operon, such as 
MGAS8232 (i.e., truncation in silD). This is a major question that has yet to be answered, 
but our work demonstrates that additional pathways independent of sil are capable of 
inducing spb expression. Based on the regulatory cues we have identified in this study, we 
predict that multiple regulators may be involved in transcriptional regulation of spb, 
including CovRS, Mga, CcpA, and LacD.1. These genes were chosen as putative regulators 
for their role in virulence factor gene expression, sugar metabolism, or in terms of their 
activation signals, which correspond with the regulatory cues required to induce spb. To 
test the possible involvement of these genes in spb regulation, we intend to generate 
deletions in each of these genes (refer to Figure 4); at this time, only the plasmid-based 
deletion constructs have been generated (Table 3). In addition, ongoing experiments in our 
laboratory are focused on elucidating the potential regulators and transporters involved in 
Spb production through transposon-mediated random mutagenesis. This involves the 
development of a transposon mutant library in MGAS8232 using the kanamycin-resistant 




Asymptomatic carriers of S. pyogenes are typically infected with one strain which persists 
in the nasopharynx for an extended period of time. In some cases, the bacteria are passively 
cleared, or in others, replaced by another GAS strain. Although serotype switching is a 
common phenomenon among group A and group B streptococci, the mechanisms which 
determine strain dominance remain unclear (12, 166). One likely mechanism used to 
explain these patterns of colonization are bacteriocins. In this study, we demonstrate that 
expression of one functional Spb system is required to establish acute infection in our 
transgenic mouse model. Loss of either SpbJK or SpbMN did not impair nasopharyngeal 
infection (Figure 9A) or ablate antimicrobial activity (Figure 9B). This is not surprising 
because we believe that these systems are redundant and used to mediate competition in 
the nasopharynx similar to other streptococci. In contrast, the bacteriocin-deficient strain 
DspbJKMN failed to establish infection consistently in the mice. Inoculation with 
DspbJKMN elicited a bimodal phenotype, by which only a fraction of mice had a 
nasopharyngeal burden similar to that of wild-type (Figure 9A). These findings suggest that 
in some cases, host factors such as the composition of the microbiota in the nasopharynx, 
allow the bacteria to establish an infection. However, a significant decrease in the bacterial 
burden recovered from murine cNTs indicates that deletion of both spb operons reduces the 
fitness of S. pyogenes in a polymicrobial environment. 
 
Bacteriocins play a crucial role in altering the composition of the microbiota in humans. In 
a particular niche, such as the gastrointestinal tract, they are able to modulate the 
microenvironment in ways that are advantageous or determinantal to certain groups of 
bacteria (167). To examine differences in microbial abundance and diversity due to Spb 
production in the nasopharynx, an in vivo time course analysis of wild-type S. pyogenes in 
the presence of the background microbiota was performed. Our analysis was limited to the 
identification of different bacteria by plating on nutrient-rich mediums, which proved not 
to be feasible. This is because differences in bacterial counts of S. pyogenes and total 
bacteria recovered from murine cNTs were very similar (Figure 8A, B), and did not provide 
the means to comprehensively evaluate all bacterial species colonizing the nasopharynx, 
including those that are unculturable in the laboratory. Therefore, it would be of interest to 
assess how infection by S. pyogenes may change the microbial composition in the 
nasopharynx overtime using a more reliable approach such as 16S rRNA gene sequencing. 
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Although there may be limitations to the approach we have utilized, our data has revealed 
an important finding. When S. pyogenes is able to establish infection, as observed by high 
bacterial loads, it appears as though no other bacteria were able to colonize the mice. This 
finding suggests that the establishment of S. pyogenes in a niche may preclude other 
bacteria from colonizing. However, it is important to note that although this mouse model 
is used to mimic acute nasopharyngeal infection, microbial population dynamics differ 
substantially in humans. Therefore, it may be advantageous to collect nasopharyngeal wash 
samples from individuals colonized with S. pyogenes, and process these samples using 16S 
rRNA sequencing. This approach has been previously utilized to characterize changes in 
the nasopharyngeal composition that contribute to asthma (168), and may provide 
important insights on population dynamics during S. pyogenes infection in humans. 
 
The BlpM and BlpN peptides produced by S. pneumoniae, which are known homologs of 
SpbM and SpbN (100), have also been studied in the context of colonization. Interestingly, 
in S. pneumoniae, previous work by Dawid et al. has shown that mutations in the blp operon 
do not impair nasopharyngeal infection when the mutant strain was instilled individually. 
However, when wild-type and blp-deficient strains were co-inoculated in equal numbers, 
the parent strain was able to outcompete the mutant, indicating that Blp production could 
interfere with colonization of blp-negative strains (101). In contrast, we have shown that 
co-inoculation impairs all spb-producing strains from establishing infection (Figure 10A). 
These results were highly unexpected and may suggest a less prominent role for Spb in 
mediating microbial interactions and a more important role in mediating GAS adherence 
compared to Blp. Although there is no exact mechanism to explain this phenomenon, one 
study has reported a similar finding. In a study by Lee et al., interactions between the gut 
microbiota and Bacteroides fragilis were examined using a germ-free murine model of gut 
colonization. They demonstrated that mice infected with one B. fragilis strain were resistant 
to subsequent colonization by another strain of the same species. Remarkably, however, 
when mice were infected with B. fragilis and challenged with another Bacteroides species, 
both able to efficiently colonize. These results suggest that certain bacteria colonize the gut 
by saturating a specific and limited niche to effectively exclude similar strains from 
establishing colonization. This observation of colonization resistance, which they have 
coined as the “saturable niche hypothesis”, is used to describe how two closely related 
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bacteria may only co-exist if they have their own particular niches (169). Based on these 
findings, we may speculate that individual S. pyogenes strains may colonize the 
nasopharynx in a similar species-specific and saturable manner. In the current study, our 
mice were challenged with two S. pyogenes strains at the same time; both of which would 
theoretically occupy the same niche. Therefore, we can presume that neither strain was able 
to effectively displace the other to establish infection. In cases where the nasopharyngeal 
burden is high, we predict that S. pyogenes wild-type was able to exclude the DspbJKMN 
strain and infect the mice (Figure 10A). To support this notion, we show that more than 
75% of colonies retrieved from coinfected mice have antimicrobial activity against M. 
luteus (Figure 10B, C). Thus, these results suggest that expression of spb may be critical 
for the establishment of nasopharyngeal infection and dominance in the host. 
 
We next investigated whether complementation in trans could restore the ability of the 
bacteriocin-deficient strain to establish nasopharyngeal infection. Despite successful 
transformation of the spbMNI genes into MGAS8232 DspbJKMN (Figure 11A), this strain 
was unable to restore colonization in transgenic mice. There was no significant difference 
between the bacterial burden of mice infected with DspbJKMN containing 
pTRKL2::PgyrA::spbMNI compared to DspbJKMN; however, an increased trend in CFU 
was observed (Figure 11B). Furthermore, it appears as though many of the colonies 
recovered for antimicrobial testing against M. luteus were sensitive to erythromycin, 
indicating that the plasmid may have been lost during infection (Figure 11C). Therefore, 
colonization defects of DspbJKMN could not be restored through plasmid-based 
complementation. Future work will aim to complement S. pyogenes MGAS8232 
DspbJKMN with spbJKL or spbMNI in cis to rescue the infection and antimicrobial 
phenotypes.  
 
Analysis of the Spb systems using qRT-PCR demonstrates that spbJ, spbK, and spbM 
expression are highly upregulated in vivo compared to in vitro growth conditions. This data, 
which is similar to previous findings from our laboratory (100), further supports the idea 
that these bacteriocins are important for mediating competition within a polymicrobial 
environment of the nasopharynx (100). Interestingly, with regard to spbJK expression, our 
preliminary data seems to suggest that the a and b-encoding genes are not transcribed in a 
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1:1 ratio. While they may be released in equal amounts for optimal activity, these findings 
suggest that the SpbK structural peptide is sequestered and/or degraded compared to SpbJ. 
To our knowledge, this is first instance which may suggest that bacteriocins of the same 
class IIb system could be transcriptionally regulated in a different manner. However, a more 
likely explanation for this phenomenon involves the immunity protein. In lantibiotics, such 
as nisin, the immunity protein is involved in sequestering the bacteriocin on the cell 
membrane (170, 171). The likely immunity protein for SpbJK, which encodes a putative 
membrane-bound metalloprotease, may also sequester SpbK in a similar mechanism to 
nisin. However, it is also possible that SpbL may directly degrade excess SpbK, similar to 
the metalloprotease immunity protein identified in Enterococcus faecalis (170, 172). 
Although it is not certain why spbK is transcribed in a greater quantity, these data provide 
strong evidence to suggest that S. pyogenes utilizes SpbJK and SpbMN bacteriocins to 
colonize the host. 
 
Host genetic factors and the composition of the microbiota contribute to a predisposition 
for developing S. pyogenes infection. In this work, we provide strong evidence that 
demonstrates that antimicrobial products, SpbJK and SpbMN, are critical for establishing 
infection in the nasopharynx. Although the mechanism has yet to be elucidated, our 
findings suggest that S. pyogenes produces bacteriocins to challenge closely related 
competitors. If this bacterium is successful, it may be able to saturate the nasopharyngeal 
niche. Our expression analyses further validate this hypothesis and show that Spb is 
produced only under in vivo growth conditions that are used to mimic a competitive 
microbial environment. In summary, our study has identified and characterized two novel 
class IIb bacteriocins that are used by S. pyogenes to establish infection and strain 
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